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CHAPTER I 
 
INTRODUCTION 
 
Current estimates from the American Cancer Society and International Union 
Against Cancer indicated that an estimated 12 million cases were diagnosed in 2008, with 
7 million deaths occurring worldwide.  Cancer is defined as a group of diseases 
characterized by the uncontrolled growth and spread of abnormal cells as a result of 
genetic alterations to the DNA.  These alterations include deletions, inversions, 
amplifications, repressions, and chromosomal translocations, all of which can lead to 
genetic instability and tumor development [1, 2].  Furthermore, these alterations can be 
potentiated by both external risk factors (tobacco, chemicals, and infection) and internal 
risk factors (inherited mutations, random mutations, and age).  Traditionally, no single 
cause, but multiple causal factors acting together or in sequence to initiate and promote 
carcinogenesis. Lack of diagnosis or proper treatment can result in spread of the cancer 
within the body and eventual death [3, 4].    
The majority of human cancers, 80-90%, arise from epithelial cells, which are 
tightly held together through several junction structures: tight junctions, adherens-type 
junctions, and desmosomes.   Development of malignant tumors, in particular the 
transition from benign to invasive, metastatic cancer, is often characterized by a tumor 
cell’s ability to overcome cell-to-cell adhesion and to invade the surrounding tissue, 
lymph system, and the circulatory system.  During the transition from a normal epithelial 
cell to a highly malignant (mesenchymal-like) cell, expression of some of these junction 
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molecules is drastically reduced or switched off [5].  This is often referred to as the 
epithelial to mesenchymal (EMT) transition, and is believed to play a prominent role in 
invasion, extravasion, and colonization during metastasis (Figure 1) [6]. 
 
 
 
Figure 1.  Primary tumor cells undergo epithelial to mesenchymal transition (EMT) and 
mesenchymal to epithelial transition (MET) which contributes to tumor heterogeneity and can 
influence the ability of select cells to metastasize.  Interactions with surrounding stromal cells 
including leukocyes and cancer-associated fibroblasts (CAF), may induce EMT resulting in 
‘migratory cancer stem cells’ which can be detected in circulation and micrometastases.  
However, distance metastasis may include differentiated epithelial cancer cells, a result of cells 
undergoing MET from local microenvironment selective pressures in order to survive (Polyak and 
Weinberg, 2009).   
 
 
Through the advancement of cancer therapy in radiation, surgical resection 
procedures, and targeted chemotherapeutic development, it has been seen that patients do 
not die from complications from the primary tumor, but from the metastatic lesions.  
Common locations for metastatic tumors to arise are the lungs, brain, and bone, which are 
areas that are more difficult to treat or have more detrimental side effects from treatment 
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[7].  Through micromestastasis that can lay dormant and go undetected for years to 
decades, metastatic tumors can arise after the primary tumor has been confirmed to be 
completely removed from the patient.  There are a variety of theories that have been 
postulated within the cancer research community, one of popularity and growing support 
is the idea of cancer stem cells.  It is believed that ‘migratory cancer stem cells’ may seed 
the metastatic microenvironments after undergoing EMT at the invasive front of the 
primary tumor and migrating into the surround tissue and circulatory system (Figure 1).  
Thus EMT plays a crucial role for the transformation of these cells to enable cellular 
detachment, dissemination, and finally metastasis [7-9]. 
As stated previously, many different cell-adhesion molecules are implicated in 
human carcinogenesis and the EMT process, and recently much attention has been 
directed towards Epithelial (E)-cadherin [10].  E-cadherin is a single-spanning 
transmembrane domain protein that forms homodimers at the cell surface membrane and 
interacts with homodimers of neighboring cells.  Aside from cell-to-cell adhesion, E-
cadherin is a key component in cell polarity induction and epithelium organization.  The 
loss of E-cadherin function elicits active signals that support tumor-cell migration, 
invasion, and metastatic dissemination.  This loss of expression during tumor progression 
can be caused by both genetic and epigenetic mechanisms; however, E-cadherin 
expression is most commonly downregulated at the transcriptional level [10]. 
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Background and Significance 
 
Colorectal cancer is the third most commonly diagnosed cancer in the United 
States and the third leading cause of cancer related deaths even though colorectal cancer 
incidence and mortality have been on the decline the past two decades.  The decrease in 
incidence and mortality can both be attributed to improvement in early detection through 
colorectal cancer awareness and colonoscopy exams, thus allowing for the removal of 
polyps before they become malignant [11].  Even so, colorectal cancer still remains a 
major leading cause of cancer related deaths, which is related to the difficulty in treating 
colorectal cancer after it has spread from the primary tumor.  In recent years, colorectal 
cancer has become a model for studying multistage carcinogenesis including the 
identification of sequential mutations, which lead to the development of colonrectal 
cancer (Figure 2) [12, 13].  This multistep process is observed in which the normal 
epithelial cells of the colon progress through a series of premalignant lesions to invasive 
and metastatic cancer with loss of E-cadherin being observed as a late stage step during 
this progression [14].   
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Figure 2.  Genetic model of colorectal carcinogenesis. 
 
 
E-cadherin was one of the first identified cadherins, and therefore has been 
thoroughly characterized in normal and pathological conditions, especially the role of E-
cadherin in metastasis.  Although E-cadherin expression can still be found in well-
differentiated solid tumors in which cell adhesion is still intact, there is an inverse 
correlation between E-cadherin levels, tumor grade, and patient mortality rates.  Loss of 
E-cadherin is commonly seen in poorly differentiated cells at the invasive front of the 
primary tumor, as well as in metastatic nodules [15-17]. One mode by which E-cadherin 
expression is lost is epigenetic silencing of CDH1 gene, which encodes the E-cadherin 
protein.  Genetic analysis of tumor samples has shown that the CDH1 gene remains 
functional, suggesting that alterations in the regulatory system are one cause for loss of 
E-cadherin expression.  For this reason, much emphasis has been put on determining 
which regulatory mechanisms are involved in silencing of CDH1 transcription and if this 
process is reversible [5, 16, 18].  
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Structure, Function, and Localization of E-cadherin Protein 
 
Cadherins are the principal component of Adherens Junctions (AJ) and 
desmosomes and the cluster at sites of cell-cell contact in most solid tissues.  E-cadherin, 
named for its presence primarily in epithelial cells, is a Type I, or ‘classical’ cadherin, 
and is involved in calcium-dependent cell-cell adhesion [10, 19].  The mature E-cadherin 
protein is comprised of 728 amino acids that form a single transmembrane domain, a 
cytoplasmic domain of about 150 amino acids, and an ectodomain of about 550 amino 
acids.  The ectodomain is comprised of 5 tandemly repeated domains separated by 
calcium binding motifs: 4 domains are ‘extracellular cadherin repeats’ and a 5th domain is 
characterized by four conserved cysteines [16, 20].   The cytoplasmic domain can be 
divided into two subdomains: the membrane proximal cytoplasmic conserved domain and 
the β-catenin binding domain.   Each cytoplasmic subdomain contains a sequence motif 
of about 30-35 amino acid residues, which are conserved among all ‘classic’ cadherins 
[21].   The cytoplasmic β-catenin binding domain, as it suggests, is the location for β-
catenin binding as well as formation of the cytoplasmic cell-adhesion complex (CCC).  
The cytoplasmic cell-adhesion complex is composed of β-catenin as well as α-catenin, ϒ-
catenin, and p120-catenin (Figure 3) [10, 22-25].   
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Figure 3.  E-Cadherin molecules are expressed at the plasma membrane and interact with 
adjacent cells through an HAV motif in the amino-terminal cadherin domain. The cytoplasmic cell-
adhesion complex (CCC) consists of β-catenin, α-catenin (on occasion ϒ-catenin) and p120-
catenin.  Through α-catenin, the CCC is linked to the actin cytoskeleton and plays a role in cell 
polarity and epithelial organization (Cavallaro and Christofori, 2004).   
 
 Both the extracellular domain and the cytoplasmic domain of the E-cadherin 
protein play important roles in the function of E-cadherin and cell-cell adhesion.  The 
extracellular domain of E-cadherin is directly involved in cell-cell adhesion, which is 
accomplished by homophilic protein-protein interactions between two E-cadherin 
molecules at the surface of neighboring cells.   This interaction is believed to be mediated 
between the most amino-terminal cadherin domains of E-cadherin proteins from adjacent 
cells.  These distal domains contain a histidine-alanine-valine (HAV) motif located 
between tryptophan residues and hydrophobic pockets, which is responsible for the 
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interactions between E-cadherin molecules [16].  Based on structural analysis using 
electron tomography it is believed that the E-cadherin molecules interact through their 
tips (HAV motifs) in cis and in trans in a highly flexible manner.  It was also shown that 
E-cadherin molecules localize in groups at the cell membrane suggesting that the 
molecular interactions occur in a zipper-like fashion (Figure 3) [26].  Through 
knockdown of E-cadherin or disruption of cadherin-mediated adhesion, it has been shown 
that both disturb or delay the functional assembly of other adhesion complexes including 
tight junctions and desmosomes [27, 28]. Although, it is worth noting that in some 
models these delays in adhesion complex formation can be overcome through alternative 
signaling pathways within the cell.  In general, research has shown that E-cadherin in 
conjunction with other cellular junctions define the physiological function of the cell; or 
how the cell will be integrated in functional structures, such as organ epithelia or stroma 
[10]. 
 As stated previously, the intracellular portion of the E-cadherin protein is the 
backbone for the cytoplasmic cell-adhesion complex, which is comprised of β-catenin, α-
catenin, and p120-catenin, and mediates the association with the actin cytoskeleton [23, 
24]. Recently, it was confirmed through use of biochemical analysis and quantitative 
microscopy that only α-catenin homodimers bind actin.  Additionally, α-catenin could 
bind efficiently to the E-cadherin/β-catenin complex, but only in its monomeric form.  
Thus α-catenin alone cannot mediate the contact of the E-cadherin/β-catenin (CCC) 
complex to the F-actin cytoskeleton [29-32].  Therefore, it is believed that there is a 
linker protein present that engages the CCC to the F-actin cytoskeleton.  To date, the 
strongest candidate for such a link between α-catenin in the CCC and the F-actin is 
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Epithelial Protein Lost in Neoplasm (EPLIN) protein.  Research has shown that EPLIN 
localizes to the apical cortical F-actin cytoskeleton in epithelial cells, has at least two 
actin binding sites, and binds to the C-terminal domain of the monomeric α-catenin in the 
CCC.  This interaction was confirmed when depletion of EPLIN from the cell resulted in 
disorganization of the actin belt, but did not affect non-junctional actin fiber formation 
[33-35]. 
In conclusion, without an intact CCC that is engaged with the actin cystoskeleton, 
cadherin-mediated strong cell-cell adhesion is compromised.  Conversely, without cell-
cell adhesion the CCC will not form, suggesting a co-dependent relationship between 
cell-cell adhesion and cellular cytoskeleton stability via the E-cadherin protein.  In 
combination, both cell-cell adhesion and CCC interaction with the actin cytoskeleton aid 
in the development of epithelial cell polarization as well as regulating signaling towards 
the formation of other junctions [15]. 
 
Importance of E-cadherin Protein in Cell-Cell Adhesion 
 
E-cadherin is involved in adherens cell-cell junctions between epithelial cells and 
plays a critical role in the establishment and maintenance of cell polarity and cell society.  
The cell-cell adherens junctions are specialized regions of the plasma membrane 
connected to the cytoskeletal actin filaments via the E-cadherin-mediated CCC and are 
believed to play a role in tissue morphogenesis [17].  These E-cadherin-mediated 
interactions in epithelial cells are important for establishing and maintaining polarity, 
preserving epithelial cell survival, and controlling proliferation.   
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When the cytoplasmic cell-adhesion complex is disrupted, intracellular 
alterations, such as release of β-catenin and γ-catenin into the cytoplasm occurs.  There 
are two pathways for β-catenin when present in the cytoplasm.  In normal epithelial cells, 
β-catenin and γ-catenin are rapidly phosphorylated by APC-GSK-3β complex and 
subsequently targeted for ubiquitinated proteasomal degradation [36, 37]. The second 
pathway for β-catenin arises during tumor progression in which mutations can occur in 
the tumor suppressor APC rendering it non-functional, as commonly seen in colon cancer 
(Figure 1), or GSK-3β can be blocked by activated Wnt signaling leading to 
accumulation of high levels of β-catenin in the cytoplasm [10].  Activated Wnt signaling 
can arise from both a positive feedback loop as well as release of Wnt ligand for 
surrounding cells thus allowing free β-catenin in the cytoplasm to localize to the nucleus.   
As a result, β-catenin activates TCF/LEF1 mediated transcription, resulting in 
upregulation of repressor transcription factors such as Twist1, Snail, and Slug [38].  
Additionally, the TCF/LEF1 family of transcription factors modulate the expression of c-
MYC, cyclin D1, fibronectin, MMP7, ID2, CD44, conductin, TCFI, and other genes all 
of which are implicated in cell proliferation and tumor progression (Figure 4) [17].   
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Figure 4.  Loss of E-cadherin alters Wnt signaling. After loss of E-cadherin function and 
disassembly of the cytoplasmic cell-adhesion complex, catenins are released and accumulate in 
the cytoplasm. β-Catenin is then sequestered by the adenomatous polyposis coli (APC)–axin–
glycogen synthase kinase 3β (GSK-3β) complex and phosphorylated by GSK-3β. Phosphorylated 
β-catenin is ubiquitinated for rapid proteosomal degradation. However, on activation of the Wnt 
signaling pathway, which is commonly seen in cancer through increased receptor activity or 
activating mutations within the signaling pathway, GSK-3β is repressed and β-catenin is no 
longer phosphorylated. It translocates to the nucleus where, together with the TCF/LEF1 
transcription factors, it modulates the expression of several target genes that are known to be 
involved in cell proliferation and tumour progression. (Cavallaro and Christofori, 2004) 
 
 
Therefore, in normal tissue, in which E-cadherin is expressed, cell-cell adhesion 
remains intact creating epithelial cell sheets.  Additionally, expression of E-cadherin, and 
the presence of the cytoplasmic cell-adhesion complex, aids in the maintenance of cell 
polarity and cell structure.  However, in cancer cells where E-cadherin expression is 
suppressed, cells may overcome adhesions to adjacent cells and dissociate from the 
primary tumor, leading to invasion of neighboring tissues and metastasis [39, 40]. 
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Epithelial to Mesenchymal Transition in Tumor Invasion and Metastasis 
  
Epithelial to mesenchymal transition (EMT) is a process by which epithelial cells 
lose many of their epithelial characteristics and take on properties that are typical of 
mesenchymal cells.  This transition requires complex changes in cell architecture and 
behavior.  Epithelial cells are characterized by forming layers of cells that are closely 
adjoined by specialized membrane structures such as tight junctions, adherens junctions, 
desmosomes, and gap junctions.  Additionally, epithelial cells have apical-basolateral 
polarization, which manifests itself through localized distribution of the adhesion 
molecules, the polarized organization of the actin cytoskeleton, and the presence of basal 
laminal at the basal surface.  Under normal conditions, the epithelial cells may become 
motile, detach, and move away from their nearest neighbors while remaining within the 
epithelial layer; however, they do not detach and move away from the epithelial layer 
[41, 42].  Conversely, mesenchymal cells do not form an organized cell layer, nor do they 
have the same apical-basolateral organization and polarization of the cell-surface 
molecules and the actin cytoskeleton as epithelial cells.  Mesenchymal cells make contact 
focally with other cells, are not typically associated with basal lamina, and migrate either 
in chains or as individual cells. However, without mesenchymal cells during 
morphogenesis, tissue and organs would never be formed. Thus, epithelial to 
mesenchymal transition is an indispensible mechanism during development [41, 43, 44]. 
 Consequently, EMT is also thought to play a central role in tumor progression. 
During progression to metastatic competence, tumor cells acquire mesenchymal gene 
expression patterns and properties, resulting in changed adhesive properties, activation of 
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proteolysis, and increased motility [41, 45].  Nascent mesenchymal tumor cells detach 
from tightly organized epithelial sheets by breaking down their tight associations or 
adherens junctions with adjacent epithelial cells.   Mesenchymal tumor cells no longer 
form sheets, display poorly organized adhesive junctions, and exhibit more fibroblastic 
characteristics (Figure 5).  Activation of proteolysis, as a result of production of 
extracellular matrix degrading enzymes, facilitates invasion of the basement membrane 
by the mesenchymal-like tumor cells, leading to entrance into the circulatory or lymph 
systems and recolonization at distant organs [46, 47].  
 
 
 
Figure 5. Regulation of the tight junctions and adherens junctions between adjacent cells affects 
the progression of EMT and MET.  The different stages during epithelial-mesenchymal transition 
(EMT) and the reverse process mesenchymal-epithelial transition (MET) are regulated by 
effectors of EMT and MET, which influence each other. (Thiery and Sleeman, 2006).      
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Much of the research conducted to confirm EMT involvement in epithelial tumor 
metastasis has been done in vitro, where epithelial carcinoma cells are induced to 
undergo EMT by growth factors, chemokines, alterations to transcriptional regulation, or 
deletion of critical adherens molecules.  Unfortunately, EMT involvement in epithelial 
tumors in vivo has been poorly documented.  This is most likely because EMT is thought 
to be a dynamic or reversible process in vivo, making it difficult to pinpoint in live 
tissues.  Specifically, migrating carcinoma cells are endowed with great cellular 
plasticity, allowing them to change shape and to revert back and forth from an epithelial 
to mesenchymal morphology in response to regulatory signals form the surrounding 
environment [46, 48].  Development of novel small molecules to target the EMT process, 
either through reversion or blocking EMT, would be an excellent tool to further elucidate 
the role of EMT during tumor progression within in vivo models.   
 
Loss of E-cadherin in Tumorigenesis 
 
 The loss of E-cadherin function during tumor progression can be caused by 
various genetic or epigenetic mechanisms.  One mode in which E-cadherin function can 
be lost is mutation in the CDH1 gene, leading to expression of a non-functional protein.  
Mutations in the CDH1 gene have been seen in diffuse gastric cancer, lobular breast 
cancer, and a lower incidence in thyroid, bladder, and gynecological cancers [49, 50].  
Somatic gene mutations are accompanied by loss of heterozygosity of the remaining E-
cadherin allele, aiding in tumor progression, while germline mutations may act early in 
the natural history of the disease [50-52].  CDH1 gene mutations include exon skipping, 
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frame shift deletions, and insertions.  Subsequent mutations can also arise in β-catenin 
and α-catenin (a very rare event) leading to disruption of the cytosplasmic cell-adhesion 
complex, preventing interaction with the actin cytoskeleton and eventual loss of cell-cell 
adhesion [53-55]. 
 Another mechanism by which E-cadherin mediated cell-cell adhesion can be 
ablated is proteolytic degradation of E-cadherin by matrix metalloproteases (MMP). In 
such a case, E-cadherin expression levels would remain normal within the cell, but 
extracellular alterations would prevent functional cell-cell adhesion establishment, aiding 
in tumor progression.  A soluble 80 kDa form of E-cadherin, produced by degradation of 
the full-length protein, is frequently found in cultured tumor cell lines and in tumor 
biopsy samples.  It has been shown that the soluble form of E-cadherin, the cleaved 80 
kDa ectodomain, promotes tumor progression, and specifically tumor-cell invasion, by 
further upregulating MMPs [10, 55]. 
 The most common mechanism by which E-cadherin expression is downregulated 
is at the transcriptional level.  Repressor transcription factors Snail, Slug, and SIP1 as 
well as the helix-loop-helix transcription factor E12/E47 have been found to bind to the 
E2 boxes in the promoter of the E-cadherin gene and actively repress transcription. As a 
direct consequence of transcriptional inactivation, the E-cadherin locus is epigenetically 
silenced by hypermethylation and deacetylation as seen in Figure 6 [56-59].  DNase I 
hypersensitive site mapping indicated the loss of transcription factor binding, resulting in 
chromatin rearrangement in the regulatory region of the E-cadherin gene.  It was shown 
through cloning and sequencing of the E-cadherin gene promoter that CpG methylation 
around the promoter region of the E-cadherin gene was present in cell lines that lacked E-
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cadherin expression.  Additionally, E-cadherin expression could be restored in these cell 
lines upon treatment with the DNA methyltransferase inhibitor 5-azacytidine [60, 61].   
 
 
 
Figure 6.  Epigenetic silencing during tumorigenesis. A transcriptionally active gene is marked by 
DNA hypomethylation of the promoter region of the gene and acetylation of the lysine residues on 
histone tails, both of which promote the formation of euchromatin. During tumorigenesis, DNA 
methylation accumulates in the promoter region, which attracts methyl-binding repressive 
proteins as well as promotes deacetylation of histone lysine residues resulting in compacted 
chromatin and transcriptional repression.  (Yoo and Jones, 2006) 
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 Additionally, deacetylation of lysine residues of histones by histone deacteylase 
(HDAC) enzymes results in chromatin compaction and inactivation of genes (Figure 6).  
Deactylation has also been shown to occur around the E-cadherin gene promoter region 
by a repressor complex comprised of Snail/HDAC1/HDAC2.  It has been shown that 
Snail preferentially binds the E2 box in the promoter region, while directly binding to 
HDAC2, and indirectly to HDAC1, in a complex.  Concurrently, treatment of cell lines 
with reduced E-cadherin expression with Trichostatin A (TSA), a Class I and Class II 
histone deacetylase inhibitor, leads to restored expression of E-cadherin in these cell lines 
[62, 63]. 
 
Targeting E-cadherin Expression Through Small Molecule Modulation 
 
E-cadherin restoration has been observed with the treatment of histone deactylase 
inhibitors (HDACi) within a variety of cancer cell lines including colon cancer, lung 
cancer, and breast cancer [64, 65].  HDACi are known to promote hyperacetylation, 
whereby they reactivate suppressed genes, such as E-cadherin, leading to activation of 
cellular differentiation programs, inhibition of the cell cycle, and induction of apoptosis 
[66].  
Further, research conducted preliminarily in non-small cell lung cancer (NSCLC) 
has shown that EMT is associated with erlotinib sensitivity.  Erlotinib is a reversible 
tyrosine kinase inhibitor to the epithelial growth factor receptor (EGFR) [67-69].   It was 
observed that lung cancer cell lines expressing epithelial proteins, such as E-cadherin and 
α- and γ-catenins, were sensitive to growth inhibition by erlotinib, whereas those cancer 
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cell lines that had undergone an EMT-like transition from an epithelial phenotype 
(expression of E-cadherin) to a mesenchymal phenotype (expression of fibronectin, 
vimentin, and the transcription factor Zeb1) were less sensitive to EGFR inhibition [68]. 
Similarly, a retrospective analysis of a phase III trial in NSCLC for erlotinib plus 
chemotherapy compared with chemotherapy alone showed that E-cadherin expression 
was a significant predictive marker for efficacy of EGFR inhibition by erlotinib, as 
measured by progression-free survival [69]. 
Haley and coworkers found a similar relationship between sensitivity to EGFR 
inhibition and the formation of adhesion junctions in colorectal and pancreatic cancer cell 
lines. They show that epithelial colorectal and pancreatic cancer cell lines were more 
sensitive than those that had undergone EMT and had a mesenchymal phenotype.  
Collectively, the data presented showed that colorectal cancer cell lines expressing E-
cadherin and β-catenin and morphologically showing an epithelial phenotype were 
sensitive to erlotinib, whereas those that had lost an epithelial phenotype, either through 
mutation or by EMT, were less sensitive as measured in maximal growth inhibition after 
a 10 μM treatment of erlotinib for 72 hours [67].  
Combining this knowledge, HDACi restoring E-cadherin expression and E-
cadherin expression being a marker for EGFR inhibitor sensitivity, it seemed logical for 
researchers to investigate the synergistic effects of HDACi and EGFR inhibitors given in 
combination.  This was done by Paul Bunn, Jr. and coworkers, wherein they first 
transfected E-cadherin into gefitinib, an EGFR inhibitor, resistant cell lines and observed 
restoration of gefitinib sensitivity.  They followed up this data, by pre-treating the cells 
with an HDACi, which induced E-cadherin along with EGFR and led to growth-
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inhibitory and apoptotic effects by gefitinib similar to those seen in gefitinib-sensitive NSCLC cell lines [70].  
Therefore, the data suggests that E-cadherin expression; specifically restoration of 
E-cadherin expression, may be a potential therapeutic target both for the prevention and 
reversion of EMT as well as resensitization of cancer cells to alternative therapies already 
in the clinic (e.g. EGFR inhibitors).  Further, several groups have demonstrated that re-
establishing the functional E-cadherin complex, such as through forced expression of E-
cadherin, resulted in a reversion from an invasive, mesenchymal phenotype to a benign, 
epithelial phenotype of cultured cancer cells [16, 40].  Thus, it seems appropriate to 
hypothesize that developing small molecules to restore E-cadherin expression would be 
therapeutically relevant for the treatment of cancer.  
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Notes on Figures, Tables, and Compound Numbering 
 
Throughout the remaining Chapters, all figure and table numbering is specific to 
each Chapter.  Put differently, each Chapter’s figure and table numbering begins with 
“1”.  Similarly, compound numbering formats and nomenclature is specific for Chapters 
II-IV and Chapter V, separately.  Arbitrary numbering (e.g. Compound 1 or (1)) is used 
interchangeably throughout each Chapter.  These are used in place of the VU registration 
codes (e.g. VU0075630) or the R/Y Lab Code (e.g. R21) in order to increase the ease and 
readability and to reduce space.  Table 1 in the Appendix 2 contains the Thesis 
numbering, VU registration code, and Y/R lab code listed for each compound (by Thesis 
numbering) to allow for ease in requesting compounds from universal storage or 
referencing laboratory notebooks.   
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 CHAPTER II 
 
IDENTIFICATION AND OPTIMIZATION OF SMALL MOLECUES THAT 
RESTORE E-CADHERIN EXPRESSION 
 
Introduction 
 
As stated previously, most human cancers arise from epithelial cells in which E-
cadherin mediated cell-cell adhesion is lost concomitantly with progression towards 
tumor malignancy.  Although E-cadherin expression can still be found in well 
differentiated tumors, there is an inverse correlation between E-cadherin expression 
levels and tumor grade [1-3].  Research has shown that inhibition of E-cadherin 
expression aids in the epithelial to mesenchymal transition in both in vivo and in vitro 
models as well as increased metastatic capabilities in in vivo models.  Currently, research 
looking at restoration of E-cadherin expression in vitro involves the use of small 
molecules such as HDAC inhibitors and DNA methyltransferase inhibitors.  HDAC and 
DNA methyltransferase inhibitors are known to restore expression of E-cadherin in cell 
lines that have a repressed functional gene [4-7].  However, upreglation of E-cadherin 
expression is merely a side effect of HDAC or DNA methyltransferase inhibition by 
these small molecules, but not the targeted phenotypic response [7].  Therefore, to further 
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understand the role of E-cadherin in the metastatic process, it is necessary to develop 
novel small molecules that are optimized to restore E-cadherin expression.   
A high-throughput screening assay can be developed to find small molecules that 
directly bind the target of interest (target-based approach) or can be developed to find 
small molecules that elicit a desired phenotypic response (phenotypic approach).  While 
target-based drug discovery has become most popular in the large biopharmaceutical 
companies, it only accounts for 23% of first-in-class drugs between 1999 – 2008 as 
compared to 37% derived using a phenotypic approach [8].  In this case, the goal was to 
identify small molecules that restored E-cadherin expression.  Therefore, a preliminary 
high-throughput screening assay was developed to discover small molecules that elicited 
a desired phenotypic response: restoration of E-cadherin expression.  The main 
disadvantage with a phenotypic readout is that the target(s) for the small molecules 
identified is unknown.  This presents a challenge for optimizing the molecular properties 
of the candidate small molecules without design parameters provided by a priori 
knowledge of the molecular mechanism of action [8].  Additionally, if several small 
molecules are indentified; potentially there could be several targets and signaling 
pathways by which these small molecules are restoring E-cadherin expression.  
Conversely, a major advantage to using a phenotypic screen is that it does not require 
prior understanding of the molecular mechanism of action, thus an assay developed for a 
phenotypic screen is more effective at translating a given disease state then target-based 
approaches, which are often more artificial [8]. 
To date, there have been no high throughput screens or drug discovery programs 
focused directly on developing small molecules that specifically upregulate E-cadherin 
 28 
expression as the primary response. For that reason, the high-throughput screening assay 
developed and utilized in our preliminary research, confirms a novel mechanism by 
which four screening hits were discovered to elicit restored E-cadherin function.  
Additionally, an optimized approach to synthesize small molecule analogs and 
screen activity was used to drive aggressive preliminary structure-activity-relationships 
(SAR) surrounding the lead hit molecule.  Basic medicinal chemistry was conducted in 
an iterative fashion using parallel libraries.  The reactions employed straightforward 
chemistry approaches in order to maximize synthetic efficiency and library size.  Each 
analog was isolated by mass-directed HPLC (Agilent Technologies) to >98% purity, 
diluted in a barcoded vial to 10 mM DMSO, and registered with a unique VU number 
that serves as an identifier for compound management. Analogs in each library iteration 
were first screened at a single point concentration (10 μM) in two assays using the 
Odyssey Infrared Imaging System: standard Western blot assay and in-cell western assay. 
DMSO was used as a negative control and TSA, a histone deacetylase inhibitor, was used 
as a positive control.  The screening data was then used to drive synthesis of future 
library iterations while a subset of selected analogs were used for further biological 
evaluation (Figure 1). 
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Figure 1. Optimized approach to efficiently synthesize and screen small analog libraries.  The 
data collected from each screen was used to develop the next library iteration, resulting in a 
relatively efficient method to probe preliminary SAR around the screening hit, compound 1.    
Thus, we developed and used a high-throughput screen to discover lead 
compounds that restored E-cadherin expression in a metastatic colon adenocarcinoma cell 
line, SW620, which exhibited low levels of E-cadherin expression.  We were able to 
develop preliminary SAR around the lead compounds using a Western blot-based E-
cadherin restoration assay (Figure 1).  In addition, we were able to develop an in-cell 
western assay with the Odyssey Imaging System to quantify EC50 values for select 
compounds. 
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Methods and Materials 
 
Cell Culture  
A colorectal adenocarcinoma cell line, SW620, and a squamous cell lung carcinoma cell 
line, H520, were obtained from the American Type Culture Collection (Manassas, VA) 
and maintained in a humidified atmosphere of 5% CO2 in air at 37 °C.  The cells were 
routinely cultured in RPMI 1640 supplemented medium with 10% fetal bovine serum 
(FBS) (Atlanta Biologicals, GA) and 100 μg/mL penicillin-streptomycin.   
High-Throughput Screen 
The metastatic human colorectal adenocarcinoma cell line SW620 was selected 
for this cell-based assay based on its low level of E-cadherin expression [9].  The high-
throughput screening assay was accomplished by modifying the E-cadherin immunoassay 
from a microscope-based protocol to an automated, HTS-compatible assay in 384 well 
plates. Variables such as cell concentration and media content, plate type, antibody 
concentrations, incubation times, and fluorescent indicators, were systematically tested to 
achieve the best overall signal-to-noise ratio and uniformity across the wells of the assay 
plates.  The optimal conditions, which best reproduced previous microscopy data 
showing Trichostatin A (TSA)-induced increases in E-cadherin staining, were determined 
as follows: groups of 10-20 batches of cell plates were seeded on 384 black-walled, clear 
bottom plates [10] at 4,000 cells/20 μL/well in RPMI (Invitrogen), 10% heat-inactivated 
FBS (Invitrogen), 1% penicillin-streptomycin (Invitrogen) for 24 hours followed by 
media exchange and 16-18 hour pretreatment of TSA control or test compounds 
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(ChemDiv, ChemBridge) in serum-free RPMI (Invitrogen) using a Vprep liquid handler 
(Velocity 11/Agilent).  Compound preparation was conducted by transferring 10 mM 
DMSO stocks of test compounds with an ECHO 550 (Labcyte) into dry polypropylene 
plates. Compounds were diluted to 10 μM in RPMI using a MicroFill (BioTek).    
Overnight compound treatment was performed at 37 °C with 5% CO2 in a Cytomat II 
Incubator (Thermo Fisher). The process of fixation and antibody staining was conducted 
using a Vprep, an ELx405 plate washer (BioTek), and Multidrop (ThermoFisher).  The 
process was integrated and time locked using a F3 robotic arm (Thermo Fisher) run with 
a Polara (Thermo Fisher) scheduler.  To decrease the time required during the screening 
process, steps from the initial microslide staining protocol were consolidated during the 
HTS validation by combining the permeabilization and blocking steps and the secondary 
antibody and propidium iodide counterstain steps. Each plate was removed from the 
Cytomat incubator in a time controlled stagger and the fixation step was completed on the 
Vprep by removing compound treatment medium and washing one time with Phosphate-
buffered Saline (PBS) (Invitrogen) followed by room temperature methanol for 15 
minutes.  Next, the cell plate was transferred to the ELx405 washer to remove methanol 
and washed for two cycles with 50 μL/well PBS.  20 μL per well of a mouse monoclonal 
anti-human E-cadherin antibody (BD Transduction Laboratories) was diluted to a 
concentration of 625 ng/mL in ice-cold PBS containing 0.2% (v/v) Triton X-100, 1% 
(w/v) BSA and added to the cell plates using the Multidrop dispenser.  The plates were 
then lidded and incubated for 60 minutes at room temperature.  Cell plates were washed 
for two cycles on the ELx405 washer with PBS.   Following the PBS wash, cell plates 
received 20 μL/well of Alexa Fluor® 488-labeled goat anti-mouse IgG  (Invitrogen) 
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diluted 1:4000 in ice-cold PBS containing 0.2% (v/v) Triton X-100, 1% (w/v) BSA, and 
0.1 μg/mL propidium iodide  (BD Biosciences). The plates were lidded and incubated at 
room temperature for 45 minutes.  Finally, the cell plates were washed on the ELx405 for 
2 cycles with PBS.   
 The cell plates were immediately imaged on an Isocyte (Blueshift 
Biotechnologies/Molecular Devices) at 10 mm resolution. The excitation wavelength was 
488 nm. Alexa Fluor® 488 and propidium iodide signals were acquired simultaneously 
using a 510-545 nm band-pass filter and a 600 nm long-pass filter respectively.  Images 
we analyzed using BlueImage 2.0 by first using the propidium iodide channel to define 
the regions occupied by cells and then interrogating the pixel intensity in this region in 
the Alexa Fluor® 488 channel. Background fluorescence was subtracted from the Alexa 
Fluor® 488 channel by subtracting values from local pixels outside the area defined by 
the propidium iodide channel mask. The data were compiled in two ways: either using a 
custom-built application to compile plate data into a final batch format of 3,200-6,400 
test samples per batch or extracted from Microsoft Excel files into summary records 
using Pipeline Pilot (Accelrys) protocols.  Hits were selected by calculating Z-scores 
based on the 320 test compound wells on each plate. Wells with Z-scores  > 3 were called 
hits. Hits were reordered from ChemBridge and ChemDiv and retested in duplicate. 
Confirmed hits were resynthesized and tested in triplicate on a concentration series 
covering a range of concentrations from 30 μM to 1.5 nM.  Compounds that produced 
concentration-dependent effects on E-cadherin expression were confirmed by mass 
spectrometry and taken forward for more extensive testing detailed below. 
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Control wells were used as quality indicators for assay performance.  Controls on 
each plate included 16 wells treated with DMSO (negative control), quadruplicate wells 
of cells treated with a dose range from 0.078 mM - 5 μM of TSA, and 16 wells plated 
with SW620sicla-1 cells which express high levels of E-cadherin promoted by stable 
siRNA knockdown of Claudin-1 [11]. For wells treated with the TSA concentration 
series that hit threshold (Z > 3) on average corresponded to 40% of the maximum dose.  
A “checkerboard” plate in which every other well was treated with either DMSO 
(negative control) or 1 μM TSA (positive control) was used as the first plate on each 
screening day to assess response uniformity and to set parameters of image analysis for 
the entire batch. The suitability for HTS was assessed daily using the Z’ statistic [12] 
with a Z’ > 0.5 indicating acceptable data. 
Compound Synthesis (1 – 285) 
Amide formation from an acid chloride:  
 A mixture containing 0.1 mmol of the acid chloride, 0.11 mmol of the amine, 0.25 
mmol of the appropriate base, such as MP-carbonate or diisopropyl ethyl amine (DIEA) 
and 2 mL of dichloromethane (DCM) was stirred or rotated for 12 hour or until reaction 
was judged complete by LCMS analysis.  The reaction mixture was filtered if necessary 
to remove resins or insoluble impurities and the solvents were removed under reduced 
pressure.  The residue was dissolved in a DMSO/methanol mixture and purified by mass-
directed HPLC to generate analogs. 
Amide formation from a carboxylic acid:  
 To a mixture containing 0.1 mmol of the carboxylic acid, 0.11 mmol of the 
appropriate amine, and 2 mL of DCM was added along with a sufficient amount of an 
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amide bond forming reagent.  Typical conditions were adding 2 equivalents of PS-
carbodiimide or 1.2 equivalents of EDCI, along with 1.2 equivalents of HOBt and 3 
equivalents of DIEA.  The reaction mixtures were allowed to stir or rotated for 12 hour or 
until reaction was judged complete by LCMS analysis.  The reaction mixture was filtered 
if necessary to remove resins or insoluble impurities and the solvents were removed 
under reduced pressure.  The residue was dissolved in a DMSO/methanol mixture and 
purified by mass-directed HPLC to generate analogs for testing. 
General Experimental:  
 All NMR spectra were recorded on a Varian Inova 400 (400 MHz) 
spectrophotometer located in the Small Molecule NMR Facility at Vanderbilt University. 
1H chemical shifts (δ) are reported in ppm values downfield from TMS as the internal 
standard. Data are reported as follows: chemical shift, multiplicity, coupling constant 
(Hz), and integration. Splitting patterns describe apparent multiplicities and are 
designated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br (broad). 
13C chemical shifts are reported in δ values in ppm. Low-resolution mass spectra were 
obtained on an Agilent 1200 LCMS with electrospray ionization. High-resolution mass 
spectra were recorded on a Waters Qt of API-US plus Acquity system. Analytical thin 
layer chromatography was performed on 250 mM silica gel 60 F254 plates. Analytical 
HPLC was performed on an Agilent 1200 analytical LCMS with UV detection at 214 nm 
and 254 nm along with ELSD detection.  Flash column chromatography was performed 
on silica gel (230-400 mesh, Merck) or using automated silica gel chromatography (Isco, 
Inc. 100sg Combiflash). 
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Compound Characterization 
Compound 1 
 
N-(2-Morpholinoethyl)-5-(thiophen-2-yl)isoxazole-3-carboxamide: 1H NMR (MeOD, 
600MHz) δ (ppm): 2.55 (s, 4H), 2.61 (t, J=6.6Hz, 2H), 3.55 (t, J=6.6Hz, 2H), 3.71 (t, 
J=4.6Hz, 4H), 6.91 (s, 1H), 7.21 (q, J=3.7Hz, J=1.2Hz, 1H), 7.765 (dd,J=4.08Hz, 
J=2.76Hz, 2H); 13C NMR (MeOD, 100MHz) δ (ppm): 37.23, 54.69, 58.36, 67.76, 99.27, 
129.13, 129.46, 130.29, 160.58, 161.10, 168.00; HRMS: C14H18N3O3S, Calculated: 
[M+H]+, 308.1069 Found: [M+H]+, 308.1070. 
Compound 54 
 
5-(Furan-2-yl)-N-(2-pyridin-2-yl)ethyl)isoxazole-3-carboxamide: 1H NMR (MeOD, 
400MHz) δ (ppm): 3.33 (m, 4H), 3.84 (t, J=6.5Hz, 2H), 6.65 (m, 1H), 6.81 (s, 1H), 7.06 
(d, J=3.5Hz, 1H), 7.75 (s, 1H), 7.84 (t, J=6.6Hz, 1H), 7.91 (d, J=8.0Hz, 1H), 8.40 (t, 
J=7.8Hz, 1H), 8.72 (d, J=5.6Hz, 1H); 13C NMR (MeOD, 100MHz) δ (ppm): 33.9, 38.1, 
97.5, 111.0, 111.7, 124.5, 127.1, 142.2, 142.5, 144.8, 145.1, 155.3, 158.4, 159.7, 162.9; 
HRMS: C15H14N3O3, Calculated: [M+H]+, 284.1035, Found: [M+H]+, 284.1035. 
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Compound 57 
 
5-(Furan-2-yl)-N-(pyridine-4-yl)butyl)isoxazole-3-carboxamide: 1H NMR (MeOD, 
400MHz) δ (ppm): 1.72 (m, 2H), 1.83 (m, 2H), 3.0 (t, J=7.5Hz, 2H), 3.45 (t, J=6.7Hz, 
2H), 6.65 (dd, J=1.76Hz, J=1.76Hz, 1H), 6.87 (s, 1H), 7.06 (d, J=3.5Hz, 1H), 7.75 (s, 
1H), 7.91 (d, J=6.4Hz, 2H), 8.68 (d, J=6.4Hz, 2H) 13C NMR (MeOD, 100 MHz) δ(ppm): 
26.7, 28.32, 34.9, 38.4, 97.6, 111.0, 111.7, 126.8, 141.5, 142.3, 145.0, 158.8, 159.6, 
162.8, 163.5; HRMS: C17H18N3O3, Calculated: [M+H]+, 312.1348, Found: [M+H]+, 
312.1350. 
Compound 73 
 
N-(2-Hydroxyphenethyl)-5-phenylisoxazole-3-carboxamide: 1H NMR (MeOD, 
400MHz) δ (ppm): 2.93 (t, J=7.1Hz, 2H), 3.62 (t, J=7.1Hz, 2H), 6.77 (m, 2H), 7.04 (m, 
2H), 7.12 (d, J=7.4Hz, 1H), 7.51 (m, 3H), 7.87 (dd, J=2.2Hz, J=1.6Hz, 2H); 13C NMR 
(MeOD, 150MHz) δ (ppm): 29.5, 38.8, 98.4, 114.5, 119.2, 125.1, 125.4, 126.7, 127.3, 
128.9, 130.3, 130.4, 155.2, 159.2, 159.8, 171.3; HRMS: C18H17N2O3, Calculated: 
[M+H]+, 309.1239, Found: [M+H]+, 309.1239. 
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Compound 116 
 
5-Phenyl-N-(4-(pyridine-4-yl)butyl-1H-pyrrazole-3-carboxamide: 1H NMR (MeOD, 
400MHz) δ (ppm): 1.72 (m, 2H), 1.84 (m, 2H), 3.1 (t, J=7.5Hz, 2H), 3.45 (t, J=6.7Hz, 
2H), 7.02 (s, 1H), 7.37 (t, J=7.36Hz, 1H), 7.45 (t, J=7.3Hz, 2H), 7.76 (d, J=7.3Hz, 2H), 
7.92 (d, J=6.4Hz, 2H), 8.68 (d, J=6.4Hz, 2H); 13C NMR (MeOD,150MHz) δ (ppm): 
26.8, 28.6, 35.0, 38.1, 101.9, 125.14,125.18, 126.8, 128.3, 128.7, 129.5, 141.5, 162.9, 
163.7; HRMS: C19H21N4O, Calculated: [M+H]+, 321.1715, Found: [M+H]+, 321.1715. 
Compound 140 
 
5-(4-Chlorophenyl)-N-(2-morpholinoethyl)isoxazole-3-carboxamide: 1H NMR 
(DMSO-d6, 600MHz) δ (ppm): 3.1 (s, 2H), 3.55 (s, 2H), 3.65 (s, 4H), 4.0 (s, 2H), 7.53 (s, 
1H), 7.65 (d, J=8.6Hz, 2H), 7.98 (d, J=8.6Hz, 2H), 9.0 (s, 1H), 9.7 (s, 1H); 13C NMR 
((CD3)2S=O, 150MHz) δ (ppm): 34.01, 51.83, 55.55, 63.76, 101.02, 125.52, 128.12, 
129.97, 136.12, 159.42, 159.86, 170.02; HRMS: C16H19N3O3Cl, Calculated: [M+H]+, 
336.1115, Found: [M+H]+, 336.1117. 
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Compound Synthesis (286 – 298) 
 
tert-Butyl (2-(5-phenylisoxazole-3-carboxamido)ethyl)carbamate:  To a solution 
containing 1.0 g (5.3 mmol) of the 5-phenylisoxazole acid and 15 mL of DCM was added 
0.94 g (5.8 mmol) of carbonyldimidazole.  The reaction mixture was allowed to stir at 
room temperature for 15 minutes and a solution containing 0.89 g (5.6 mmol) of the tert-
butyl (2-aminoethyl)carbamate in 5mL of DCM was added, followed by 2 mL (11 mmol) 
of DIPEA.  The reaction mixture was allowed to stir at room temperature overnight, 
quenched by the addition of water, and extracted with DCM. The combined organic 
layers were dried by passage through a phase separator cartridge and the solvent was 
removed under reduced pressure.  The residue was subjected to silica gel chromatography 
to give 1.2 g (76%) of tert-butyl (2-(5-phenylisoxazole-3-carboxamido)ethyl)carbamate 
as a white solid. LCMS: 1.20 min, m/z = 354.2 [M+Na]+. 
 
tert-Butyl (3-(5-phenylisoxazole-3-carboxamido)propyl)carbamate: In a similar 
manner to above, 0.32 g (92%) of tert-butyl (3-(5-phenylisoxazole-3-
carboxamido)propyl)carbamate was prepared from 0.38 g (2.0 mmol) of 5-
phenylisoxazole acid and 0.2 g (1.1 mmol) of (3-aminopropyl)carbamate. LCMS: 1.22 
min , m/z = 368.2 [M+K]+. 
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tert-Butyl (2-(5-phenyl-1H-pyrazole-3-carboxamido)ethyl)carbamate: In a similar 
manner, 0.39 g (57 %) of tert-butyl (2-(5-phenyl-1H-pyrazole-3-
carboxamido)ethyl)carbamate was prepared from 0.38 g (2.2 mmol) of 5-phenyl-1H-
pyrazole-3-carboxylic acid and 0.35 g (2.2 mmol) of (2-aminoethyl)carbamate. LCMS: 
1.06 min , m/z = 354.2 [M+Na]+. 
 
N-(2-Aminoethyl)-5-phenylisoxazole-3-carboxamide: A solution containing 1.21 g (3.7 
mmol) of tert-butyl (2-(5-phenylisoxazole-3-carboxamido)ethyl)carbamate, 15 mL of 
DCM and 3 mL of TFA was allowed to stir at rt overnight. The solvents were removed 
under reduced pressure to give a quantitative yield of N-(2-aminoethyl)-5-
phenylisoxazole-3-carboxamide as its trifluoroacetic acid salt as a white solid.  LCMS: 
0.77 min, m/z = 232.2 [M+H]+ 
 
N-(3-Aminopropyl)-5-phenylisoxazole-3-carboxamide: In a similar manner, 0.21 g 
(99.8%) of N-(3-aminopropyl)-5-phenylisoxazole-3-carboxamide as its trifluoroacetate 
salt was obtained as a yellow oil from 0.31 g (1.44 mmol) of tert-butyl (3-(5-
phenylisoxazole-3-carboxamido)propyl)carbamate: LCMS: 0.79 min, m/z = 246.3 
[M+H]+ 
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N-(2-Aminoethyl)-5-phenyl-1H-pyrazole-3-carboxamide: In a similar manner, 0.28 g 
(99.8%) of N-(2-aminoethyl)-5-phenyl-1H-pyrazole-3-carboxamide: as its 
trifluoroacetate salt was obtained as a yellow oil from 0.39 g (1.44 mmol) of tert-butyl 
(2-(5-phenyl-1H-pyrazole-3-carboxamido)ethyl)carbamate: LCMS: 0.67 min, m/z = 
231.3 [M+H]+. 
General procedure for amide bond formation:  
 To a mixture containing 1.1 eq of the appropriate acid, 1mL of DCM, and 1 mL 
of DMF was added 1.5 eq of HATU or 1.5 eq of EDC and 1.5 eq of HOBt.  The reaction 
mixture was allowed to stir at room temperature for 15 minutes and a solution containing 
1.0 eq of the appropriate amine, 3 eq of Hunig’s base, and 1 mL of DMF was added.  The 
reaction mixture was allowed to stir overnight.  The solvents were removed under 
reduced pressure and the residue was purified by HPLC. 
Compound 289: 
 
N-(3-(2-Hydroxynicotinamido)propyl)-5-phenylisoxazole-3-carboxamide: Following 
the general procedure starting with 0.15 mmol of N-(3-aminopropyl)-5-phenylisoxazole-
3-carboxamide, 14 mg (23%) of N-(3-(2-hydroxynicotinamido)-propyl)-5-
phenylisoxazole-3-carboxamide was prepared as a white solid: 1H NMR (400MHz, 
CD3OD): δ 8.47 (dd, 1H, J = 11.2 and 2.0 Hz), 7.88-7.86 (m, 2H), 7.64 (dd, 1H, J = 6.4 
and 2.0 Hz), 7.55-7.51 (m, 3H), 7.07 (s, 1H), 6.55 (t, 1H, J = 6.4 Hz), 3.54-3.48 (m, 4H), 
and 1.94-1.91 (m, 2H); LCMS: 0.98 min, m/z = 367.2 [M+H]+. 
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Compound 290: 
 
N-(3-(Isonicotinamido)propyl)-5-phenylisoxazole-3-carboxamide: Following the general procedure starting with 0.10 mmol of N-(3-aminopropyl)-5-phenylisoxazole-3-carboxamide, 18 mg (45%) of N-(3-(isonicotinamido)propyl)-5-phenylisoxazole-3-carboxamide was prepared as a white solid: LCMS: 0.95 min, m/z = 351.2 [M+H]+. 
Protein Expression – Western Blot Analysis 
 SW620 and H520 cells (7.5 x 105/mL) were seeded in 6 well plates for 24 hours 
prior to treatment. Cells were treated with a 10 μM concentration of synthesized 
compound for 24 hours in RPMI 1640 supplemented medium and 100 μg/mL penicillin-
streptomycin. Total protein was isolated from cells with the use of RIPA lysis buffer with 
protease inhibitors. Lysates were sonicated for 10 seconds, incubated on ice, and 
centrifuged at 13,000 rpm for 15 minutes at 4 °C. Protein concentration was measured by 
absorbance at 595 nm using the Bradford assay reagent (Bio-Rad, Hercules, CA) with 
bovine albumin standards. 10 μg of proteins were loaded per sample onto 10% SDS-
polyacrylamide gels that were run at 100V for approximately 1.5 hours.  Proteins were 
electrophoretically transferred to polyvinylidene difluoride (Bio-Rad, Hercules, CA) 
membranes at 100V for 2 hours. After completion of transfer, the polyvinylidene 
difluoride membrane was incubated with 10 mL LI-COR blocking buffer (1:1 dilution in 
PBS; LI-COR Biosciences, Cambridge, UK) for 1 hour at room temperature with gentle 
agitation.  To determine E-cadherin expression level, the membrane was incubated 
simultaneously with the anti-E-Cadherin (1:2000; BD Transduction Laboratories, San 
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Jose, CA) and anti-α-Tubulin (1:20,000; Abcam, Cambridge, MA) in 10 mL LI-COR 
blocking buffer (1:1 dilution in PBS) with gentle agitation overnight at 4 °C. The next 
day, the antiserum was removed and the membrane was washed 3 times in PBS with 
0.1% Tween (PBS-T) before addition of secondary antibody conjugated to a fluorescent 
entity: IRDye 800-conjugated goat anti-mouse IgG (1:10,000) and IRDye-700-
conjugated goat anti-rabbit IgG (1:10,000) in 10 mL LI-COR blocking buffer (1:1 
dilution in PBS) with gentle agitation for 1 hour at room temperature. At the end of the 
incubation period, membranes were washed 3 times with PBS-T. The membrane was 
visualized and analyzed on the Odyssey IR imaging system (LI-COR Biosciences).  
Protein Expression – In Cell Western Analysis 
 SW620 and H520 cells (10 x 104/100 μL) were seeded in a 96-well plate prior to 
treatment. Cells were treated with a 10 μM concentration of synthesized compound in 
quadruplicate for 24 hours in RPMI 1640 supplemented medium and 100 μg/mL 
penicillin-streptomycin. The cells were then fixed with 100% methanol for 20 minutes at 
4 °C.  The wells were then washed 2 times with PBS, permeabilized in 2% bovine serum 
albumin (BSA) and 0.2% Triton X-100 in PBS for 30 minutes at room temperature with 
gentle agitation, and blocked in LI-COR blocking buffer for 30 minutes at room 
temperature with gentle agitation.  The cells were then incubated with the following 
primary antibodies: anti-E-Cadherin (1:500) and anti-α-Tubulin (1:1000) diluted in LI-
COR blocking buffer (1:1 dilution in PBS) for 2 hours at room temperature with gentle 
agitation.  The cells were washed 4 times in PBS-T for 5 minutes each, and then 
incubated with the following secondary antibodies conjugated to a fluorescent entity: 
IRDye 800-conjugated goat anti-rabbit IgG (1:2000) and IRDye 700-conjugated goat 
 43 
anti-mouse IgG (1:2000) in LI-COR blocking buffer (1:1 dilution in PBS) with gentle 
agitation for 1 hour at room temperature.  The cells were washed 4 times in PBS-T for 5 
minutes each followed by a single wash with PBS.  All liquid was removed from the 
wells and the plates were visualized and analyzed on the Odyssey IR imaging system (LI-
COR Biosciences). 
 The assay was further optimized in the following manner.  The cells were washed 
2 times with PBS, fixed in 100% methanol at room temperature for 15 minutes, and again 
washed 2 times with PBS. The cells were then incubated with the following primary 
antibodies: anti-E-Cadherin (1:200) and anti-α-Tubulin (1:2000) diluted in ice cold 2% 
bovine serum albumin (BSA) and 0.2% Triton X-100 in PBS for 1 hour at room 
temperature with gentle agitation. The cells were washed 2 times in PBS and then 
incubated with the following secondary antibodies conjugated to a fluorescent entity: 
IRDye 800-conjugated goat anti-rabbit IgG (1:2000) and IRDye 700-conjugated goat 
anti-mouse IgG (1:2000) in ice cold 2% BSA and 0.2% Triton X-100 in PBS with gentle 
agitation for 45 minutes at room temperature.  The wells were washed 2 times in PBS, 
dried, and analyzed as previously mentioned. 
 The assay was optimized a third, and final, time in the following manner.  The 
cells were fixed in ice-cold 100% methanol at room temperature for 15 minutes and 
washed 2 times with PBS.  The cells were blocked for 45 minutes in LI-COR blocking 
buffer (1:1 in PBS with 0.2% Triton X-100) then incubated with the following primary 
antibodies: anti-E-cadherin (1:500) and anti-α-tubulin (1:2000) diluted in LI-COR 
blocking buffer (1:1 dilution in PBS) for 1 hour at room temperature.  The cells were 
washed 3 times in PBS (final wash for 10 minutes) and then incubated with the following 
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secondary antibodies conjugated to a fluorescent entity: Licor 800-conjugated goat anti-
rabbit IgG (1:2000) and IRDye-700-conjugated goat anti-mouse IgG (1:2000) in LI-COR 
blocking buffer (1:1 dilution in PBS) for 45 minutes at room temperature.  The wells 
were washed 3 times in PBS (final wash for 10 minutes), covered with 50 μL of PBS, and 
analyzed as previously mentioned. 
 
Results 
 
High-Throughput Screen to Discover Lead Compounds  
A phenotypic assay suitable for high-throughput screening was developed to 
identify small molecules that restore E-cadherin expression in SW620 cells.  The screen 
detects E-cadherin restoration at the cell membrane after a 16-18 hour incubation with 
test compounds via the use of an anti-E-cadherin monoclonal antibody and subsequent 
secondary antibody-based Alexa Fluor® 488 visualization. Images were obtained using a 
novel plate-based laser-scanning fluorometer, Blueshift Isocyte, that is capable of 
obtaining images at 2.5-10 µm resolution in all wells of a 384 well plate in 2-10 
minutes/plate.  For quantification, a second channel of data was obtained by staining cells 
with propidium iodide. The propidium iodide counterstain labels cellular nucleic acids, 
allowing E-cadherin expression levels, as judged by Alexa Fluor® 488 fluorescence, to be 
normalized to cell number on a per-well basis (Figure 1). The image analysis was 
performed using BlueImage 2.0 and data were compiled into reports using custom-
written applications and Pipeline Pilot. In order to judge assay performance, positive and 
negative controls were run on each plate.  The positive controls consisted of a small 
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molecule HDAC inhibitor, TSA, and SW620sicld-1 cells, which express high levels of E-
cadherin by virtue of siRNA knockdown of Claudin-1.  After optimization, the screen 
was found to be suitable for screening in 384 well plates with a Z’ averaging > 0.5 
(Figure 1). The entire optimized assay protocol was automated on a robotic screening 
system built around an F3 robotic arm (Thermo Fisher) running on a Polara scheduler 
(Thermo Fisher).  
 The automated assay was used to conduct a high-throughput screen of 
83,200 small molecules from the Vanderbilt Institute of Chemical Biology library, which 
was built using a diverse set of molecules available from the ChemDiv and Chembridge 
collections. The hit threshold was set at 3 standard deviations above the average 
fluorescent intensity calculated from the test compound wells. The screen revealed thirty 
confirmed hits, four of which produced concentration-dependent effects in the primary 
screening assay. 
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Figure 2. A high-throughput screen using immunofluorescent staining of human colorectal cancer 
cells (SW620) identified increased E-cadherin expression with treatment of compounds from the 
Vanderbilt Institute of Chemical Biology small molecule library.  Dual-color acquisition images 
show the E-cadherin levels of four representative wells from a 384-well assay plate. The table 
shows average values for positive (TSA, Claudin-1 KO) and negative (DMSO) controls and a 
compound selected from the primary screen. 
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Preliminary SAR 
Among the confirmed and validated hits from the initial E-cadherin restoration 
screen were four compounds with somewhat similar chemotypes (Figure 2).  Each of the 
hit structures was re-synthesized using standard chemistry routes, and the re-synthesized 
molecules were tested to confirm activity in an E-cadherin restoration assay. As it is 
known that iron loading can play a role in the expression of E-cadherin [2], and that acyl 
hydrazone based on compounds 2, 3, and 4 structures can chelate iron effectively [3, 13],  
we elected to focus our optimization efforts on compound 1.  Employing a parallel 
synthesis library approach, we first explored the eastern amine tail of 1 while maintaining 
the western 2-thiophenylisoxazole core.  This first generation library explored a wide 
range of functionalized amines as well as structural fragments from 2, 3, and 4.   
 
 
 
Figure 3.  Selected hits 1-4 from the E-cadherin restoration screen.   
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Selected results from the first libraries are shown in Table 1, wherein compounds 
were synthesized using standard amide bond forming reactions using commercially 
available carboxylic acids or acid chlorides and amines.  All compounds were evaluated 
initially at 10 µM in a Western blot assay measuring the ability of the compounds to 
restore E-cadherin expression in SW620 cells, using TSA as a positive control. The data 
are expressed as fold change in E-cadherin expression above the DMSO control 
treatment. Compound 1, the resynthesized HTS hit, was confirmed with a 5.68-fold 
increase in E-cadherin expression.  Elongating the linear linker that serves to attach the 
morpholine in compound 24 produced only a slight diminishment of activity (3.51-fold).  
However, removing the oxygen atom of the morpholine (11) led to a sharp decrease in 
potency (0.96-fold).  Several additional attempts to tether a basic amine onto the structure 
(8, 18, 20) also were met with little success.  Interestingly, replacement of the morpholine 
moiety in 1 with an ether (9) afforded a compound of only slightly reduced efficacy (4.3-
fold).  In addition, a number of heteroaromatic moieties (6, 17, 21, 32) were well 
tolerated as morpholine replacements (4.9- to 13.2-fold).  In particular, the imidazole 21 
(8.11-fold) and the pyridine 32 (13.25-fold) produced compounds more efficacious than 
compound 1. Interestingly, substitution on the amide nitrogen is not tolerated, as 35, the 
N-Me analog of 32 (13.2-fold), provides only a 1.63-fold increase in E-cadherin 
expression. Additional analogs with a substitution on or adjacent to the amide nitrogen, 
such as compounds 12-15, also displayed sharply reduced potency. Overall, these 
preliminary libraries provided robust SAR and suggest that the presence of a hydrogen 
bond acceptor may be a key structural feature leading to enhanced E-cadherin expression.  
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Table 1. Synthesis and evaluation of initial compound library.  Variation to the eastern portion of 
compound 1. 
 
 
Compound R WB
a 
SW620 
WBa 
H520 
ICWb 
SW620 
ICWb 
H520 
 
1 
  
 
5.68 5.55 2.19 4.79 
 
5 
  
 
7.30 10.06 5.03  
 
6 
   
6.98 9.68 4.71  
 
7 
   
5.05 10.01   
 
8 
 
 
 
 
0.97 1.20   
 
9 
 
 
 
 
4.29 8.05 3.88  
 
10 
 
 
 
 
5.34 8.01 4.43  
 
11 
 
 
 
 
0.96    
 
12 
  
 
0.84    
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13 
 
 
 
0.92    
 
14 
 
 
 
0.90    
 
15 
  
 
0.75    
 
16 
 
 
 
0.80    
 
17 
  
 
4.97  5.41  
 
18 
  
 
0.86    
 
19 
  
 
1.36 3.24   
 
20 
  
 
1.13    
 
21 
   
8.11 10.84 4.15  
 
22 
  
 
1.19    
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23 
  
 
1.12    
 
24 
  
 
3.51 6.10 2.71  
 
25 
  
 
1.06    
 
26 
   
1.25    
 
27 
  
 
1.18    
 
28 
  
 
1.13    
 
29 
  
 
2.29 1.97 1.17 1.10 
 
30 
  
 
2.71 2.89 4.21  
 
31 
  
 
12.90 4.55 4.49  
 
32 
  
 
13.25 4.62 3.50  
 
33 
   
2.50  0.72 1.65 
 
34 
 
 
 
8.91 
 
9.20 
 
4.44 
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35 
 
 
 
 
1.63 
  
0.91 
 
0.83 
 
36 
 
 
 
 
8.44 
 
5.38 
 
3.96 
 
4.59 
 
37 
 
 
 
   
1.19 
 
2.12 
 
38 
 
 
 
   
1.17 
 
0.56 
 
39 
  
 
   
3.81 
 
3.84 
 
40 
  
 
  3.10 4.16 
 
41 
  
 
  2.58 2.28 
 
42 
  
 
  0.14 1.76 
a Data is fold change in E-cadherin restoration above a DMSO control as measured by Western blot for compound 
treatment at 10 µM. (TSA = 3.74). 
b Data is fold change in E-cadherin restoration above a DMSO control as measured by In-Cell Western assay for 
compound treatment at 10 µM. (TSA = 2.37). 
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Optimization of Lead Compound 1 
With SAR in hand regarding the eastern amide moiety, we next decided to 
employ a matrix library approach to explore the western heterobiaryl fragment of 1, using 
the eastern amines identified in the first generation library effort (Table 2). We also 
pursued expansions of the SAR around the amine tail groups of particular interest, 
especially the pyridine tails of 17 and 32.  Selected compounds from Table 1 are included 
for comparison.  As with the morpholine, chain length extension proved successful with 
an ether-based tail (compare 9 and 10).  The 2-pyridyl congener 31 (12.9-fold) was more 
than 2-fold more potent compared with 17 (4.97-fold), being essentially the equal of the 
4-pyridyl isomer 32 (13.2-fold).  While a shortened tether was not successful (not 
shown), the longer butyl chain of 34 afforded good activity (8.9-fold).   
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Table 2. Optimization matrix library based on the initial compound 1 analog series. 
Substituent 
        
 
1 
4.25 
(1.91) 
47 
1.13 
(1.25) 
132 
1.14 
(1.01) 
75 
5.38 
(2.80) 
187 
1.09 
(1.06) 
179 
1.88 
(1.08) 
140 
1.71 
(0.94) 
124 
1.44 
(0.95) 
 
24 
3.51 
(2.71) 
49 
1.18 
(1.61) 
134 
0.96 
(0.96) 
67 
2.43 
(1.29) 
N/A N/A 
145 
1.00 
(1.28) 
117 
0.96 
(0.73) 
 
9 
4.29 
(3.88) 
43 
2.43 
(1.58) 
128 
1.01 
(1.23) 
162 
3.71 
(2.59) 
188 
1.08 
(0.94) 
180 
2.92 
(2.15) 
139 
1.94 
(1.32) 
114 
1.29 
(0.87) 
 
10 
5.34 
(4.43) 
44 
3.55 
(3.90) 
129 
1.0 
(0.90) 
63 
4.98 
(3.37) 
189 
1.17 
(1.01) 
181 
3.78 
(1.91) 
141 
2.09 
(1.01) 
106 
2.10 
(1.28) 
 
21 
8.11 
(4.15) 
46 
2.72 
(3.92) 
131 
1.20 
(1.13) 
80 
4.66 
(5.20) 
191 
1.52 
(1.34) 
183 
3.54 
(3.01) 
144 
1.97 
(1.08) 
115 
1.27 
(1.04) 
 
6 
6.98 
(4.71) 
51 
3.17 
(5.89) 
136 
1.06 
(0.99) 
68 
4.99 
(2.26) 
193 
1.5 
(0.80) 
185 
4.2 
(1.50) 
147 
1.07 
(1.14) 
109 
2.78 
(2.09) 
 
31 
12.9 
(4.49) 
54 
6.53 
(3.64) 
N/A 
69 
11.99 
(3.51) 
N/A N/A N/A 
111 
1.72 
(1.07) 
 
17 
4.97 
(5.41) 
45 
4.50 
(6.46) 
130 
1.23 
(1.52) 
65 
4.78 
(2.36) 
190 
1.79 
(1.14) 
182 
4.48 
(3.78) 
142 
2.01 
(1.45) 
107 
2.67 
(1.61) 
 
32 
13.25 
(3.50) 
55 
8.60 
(3.02) 
N/A 
70 
13.69 
(1.16) 
N/A N/A N/A 
112 
3.50 
(1.71) 
 
34 
8.91 
(4.44) 
57 
9.6 
(6.33) 
N/A 
72 
9.60 
(4.36) 
N/A N/A N/A 
116 
7.66 
(5.68) 
 
5 
7.30 
(5.03) 
50 
4.11 
(4.54) 
135 
0.96 
(0.95) 
73 
11.25 
(5.80) 
192 
1.48 
(1.19) 
184 
1.72 
(1.43) 
146 
1.31 
(1.50) 
122 
6.41 
(1.81) 
 
36 
8.44 
(3.12) 
59 
7.98 
(1.37) 
N/A 
77 
2.52 
(0.91) 
N/A N/A N/A 
119 
10.27 
(1.48) 
 
30 
2.71 
(4.21) 
53 
2.82 
(3.64) 
138 
0.94 
(1.12) 
88 
2.32 
(2.00) 
194 
1.7 
(0.90) 
186 
2.96 
(1.76) 
148 
0.90 
(0.94) 
110 
4.16 
(1.73) 
 
a Data is fold change in E-cadherin restoration above a DMSO control as measured by Western blot or In-Cell Western 
(as seen in parentheses) for compound treatment at 10 µM; N/A = not synthesized (TSA = 3.74 Western blot; 2.37 ICW). 
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Interestingly, we found that phenyl rings with ortho substituents, e.g., 2-
chlorophenyl derivative (36) and 2-hydroxylphenyl derivative (5), maintained efficacy.  
In terms of western heterobiaryl SAR, we found that unsubstituted isoxazoles were 
devoid of activity (data not shown), but a furyl moiety on the western portion of the 
molecule was a reasonable alternative for the thiophene ring.  A methyl thiazole proved 
to be inferior to the thiophene in nearly all cases.  A phenyl ring was found to be an 
essentially equipotent replacement for the thiophene, however differences were noted 
depending on the nature of the amine in the eastern tail.  Interestingly, neither a pyridine 
(187), an ortho-flouro (179) nor a para-chloro (141) substitution were well tolerated with 
the morpholine based amine, demonstrating a 2-fold reduction in activity relative to the 
phenyl substitutent.  However, with other eastern moieties, including the ether (181), 
imidazole (183), furyl (185) and pyrimidinyl (182) containing amines, the ortho-flouro 
derivative retains potency.  Finally, mixed success was obtained with the introduction of 
heteroaryl substituents, inspired by the acyl hydrazone hits 2-4, into the western portion.  
A 4-pyridyl analog was uniformly inactive (not shown) whereas the phenyl pyrazole from 
2 retained activity in several examples, the best of which (116 and 119) possessed 
potency as much as 2-fold better than the initial hit 1. The overall SAR for this matrix 
library was intriguing, as increased expression of E-cadherin was dependent on the nature 
of both the eastern and western fragments. 
Synthesis of the most resent libraries focused on changes within the linker region 
to try and expand the SAR through addition of points for further building off the central 
carbon linker (Table 3).  Originally, the changes made to the linker where in an effort to 
open up the central carbon linker for potential addition of photoaffinity labels, for future 
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efforts towards identifying the molecular target.  Additionally, hydrogen bond donor and 
acceptor moieties were moved around the pyridine ring in order to determine which 
position(s) and moiety types were best tolerated.  When these molecules were screened in 
the ICW assay in both the SW620 and H520 cells many were seen to have improved E-
cadherin restoration as compared to the previously profiled compounds.  In addition, 
EC50 values of select newly synthesized analogs were much lower, hovering around 1 
μM.  Further discussion of the EC50 values will occur in Chapter 3.    
 
 
Table 3.  General synthesis scheme and representative library of analogs that include an amine 
tethered carbon linker in the mid-section of the molecules. 
 
Compound X n R ICW
a 
SW620 
EC50 
(μM) 
ICWa 
H520 
EC50 
(μM) 
 
286 
 
NH 1 
 
1.37  1.24  
 
287 
 
NH 1 
 
1.45  1.04  
 
288 
 
NH 1 
 
1.77  1.10  
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289 
 
O 2 
 
5.23 5.0 5.54 1.0 
 
290 
 
NH 1 
 
1.29  1.22  
 
291 
 
O 2 
 
4.92 4.97 5.92 1.5 
 
292 
 
O 2 
 
2.92 5.0 5.27 1.4 
 
293 
 
O 2 
 
1.62  1.88  
 
294 
 
O 1 
 
3.40 3.7 3.51 5.6 
 
295 
 
O 1 
 
2.79 8.8 2.87 5.1 
 
296 
 
O 1 
 
1.18  1.14  
 
297 
 
O 1 
 
8.98 4.8 4.22  
 
298 
 
O 1 
 
3.05 7.1   
a Data is fold change in E-cadherin restoration above a DMSO control as measured by In-Cell Western assay for 
compound treatment at 10 µM. (TSA = 2.37 in SW620 cell line). 
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Screening of Analogs to Quantify E-cadherin Restoration 
 The initial HTS screening hits were confirmed using a standard Western blot 
procedure using enhanced chemiluminescence (ECL) to detect E-cadherin protein on the 
Western blot membrane (Figure 4).  The major disadvantage to using ECL was that we 
were unable to quantify the band intensity and thus were left making decisions on the 
compounds’ abilities to restore E-cadherin expression by comparing band intensity and 
size by eye.   
 
 
 
Figure 4. Preliminary Western blot to confirm restoration of E-cadherin protein expression by 
positive screening hits.  SW620 cells were treated with a 10 μM treatment for 24 hours.  DMSO is 
used as a negative control, TSA is used as positive control, and β-actin is used as a loading 
control.  Additionally, the chemical structure for TSA and BJ4 (another positive screening hit) are 
displayed on the right.   
This method of analysis continued through several preliminary libraries of 
compound 1 analogs until we decided to take advantage of the fluorescent secondary 
antibodies used with the Odyssey Imaging System allowing for the quantification of 
 59 
fluorescent band intensity.  By quantifying the E-cadherin band intensity for each 
compound we were able to calculate the fold change by normalizing to the DMSO 
control treatment.  This allowed for a more accurate comparison of compounds to the 
negative control (DMSO), positive control (TSA), and original screening hit (1).  
Representative blots from the SW620 and H520 cells treated with selected analogs can be 
seen below.  Additionally, the derived graphs below confirm that changes in E-cadherin 
expression can be both visualized and quantified (Figure 5). 
 
 
 
Figure 5. Representative images of Odyssey Imaging System Western blot read-out from SW620 
(left) and H520 (right) protein samples and the subsequent calculation of fold change as 
normalized to the DMSO control.  Cells were treated for 24 hours with a single point 10 μM 
treatment.  Whole cell lysates were collected and subjected to Western blot analysis.  Samples 
were probed for E-cadherin; Tubulin was the loading control. Values were quantified as the fold 
change in E-cadherin expression above the DMSO control. 
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 Ultimately, we wanted to develop a method that would be high throughput and 
allow for replicate testing of the synthesized analogs.  Piggy-backing from the original 
HTS assay and our use of the Odyssey Imaging System, we developed and utilized an In-
Cell Western (ICW) assay.  The ICW assay would allow for triplicate or quadruplicate 
replicates for each concentration and direct quantification of the intensity of fluorescent 
secondary antibody in each well.  In addition, we could screen up to 32 compounds per 
96-well plate instead of 15 compounds per Western blot.  Use of the ICW assay also 
allowed for fixation, staining, and analysis of the treatments in a single day, 
approximately 3 hours, as opposed to an overnight incubation with primary antibody 
necessary with the Western blot. Preliminarily, an optimized single point, 10 μM 
concentration, ICW assay was developed and representative wells with calculated data 
for both the SW620 and H520 cell lines can be seen in Figure 6.  While the sensitivity 
was not as great in the ICW, it did trend with the Western blot data, suggesting that such 
an assay could be utilized to screen all future synthesized analog libraries; data for which 
can be seen in Table 2 and Table 3. 
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Figure 6.  Snap shot images of the Odyssey Imaging System read-out for the ICW assay with the 
SW620 (top) and H520 (bottom) cells and the subsequent calculation of fold change as 
normalized to the DMSO control.  Cells were treated for 24 hours with a single point 10 μM 
treatment. After treatment, cells were fixed, permeabilized, and probed for E-cadherin and 
Tubulin (control). The In-Cell Western assay measured fluorescence intensity of the secondary 
antibodies directly in each well as seen above using the Odyssey Imaging System.  For each 
treatment the intensity values were averaged and normalized to the DMSO control at 1; this is 
shown as fold change in the corresponding graph. 
 
 
Discussion 
 
Here we have shown the development and application of two unique assays.  The 
first is a novel high-throughput screen used to identify compounds capable of restoring E-
cadherin expression levels in SW620 cells, which are deficient in E-cadherin.  The use of 
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a phenotypic assay to identify a lead compound is very rare and comes with several 
hurdles.   The major hurdle is that mechanism of action and specifically the molecular 
target for which the active compounds are binding remains unknown.  However, there are 
two major advantages to phenotypic screening assay.  One is that the desired phenotypic 
response, E-cadherin protein expression, is achieved in the positive screening hits.  The 
other is that since the desired response is being achieved by positive screening hits it is 
known that molecules are able to cross the cell membrane, a problem seen when in vitro 
enzymatic and biochemical assays developed for a specific protein’s activity are used to 
screen synthesized analogs prior to cell-based experiments.   
The second assay developed was an ICW assay that permitted the quantification 
of E-cadherin restoration in a relatively high-throughput manner using the Odyssey 
Imaging System.  Several iterations of the ICW assay protocol allowed for further 
reduction in assay length as well as increased sensitivity such that the fold changes 
calculated for compounds were more similar to those seen by the standard Western blot 
procedure.  Increased sensitivity allowed for clear separation between active and inactive 
compounds, and thus the standard Western blot was not needed for confirmation. This 
allowed for screening solely using the ICW assay.   Overall, the ICW assay allowed for 
single point screening of synthesized compound libraries in triplicate or quadruplicate.  It 
also allowed for the establishment of concentration response curves, and quantification of 
an EC50 value, for each positive compound, which will be discussed in the following 
Chapter.      
Further, a matrix library approach, conducted using iterative parallel library 
synthesis, was undertaken in order to examine a broad spectrum of chemical alterations to 
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both the eastern amine tail and the western heterobiaryl portion of the original lead 
compound.  Such an approach allowed for a relatively rapid synthesis of nearly 100 
compounds that were preliminarily screened in both the Western blot and/or ICW assays.  
This permitted the visualization of chemical structural trends, allowing for more specific 
library synthesis in order to further optimize the original lead compound, 1.   
In an effort to expand the SAR through the middle section carbon linker, we were 
able to identify compounds that further improved the restoration of E-cadherin protein 
expression.  Insertion of a carbon linker attached to the western and eastern portions of 
the molecule by amines will provide additional areas to expand the molecule.  This may 
also allow for the insertion of a photoaffinity moiety, such as an azide, in order to utilize 
affinity chromatography as a mechanism by which to identify the molecular target.   
In total, 300 compounds have been synthesized and screened to date, with the 
identification of a handful of compounds that restore E-cadherin expression greater then 
9- to 10-fold in both the SW620 and H520 cells in the Western blot assay, and greater 
then 7-fold in the ICW assay.  All synthesized compounds to date can be seen in 
Appendix 1, Tables 1-20 at the back. 
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CHAPTER III 
 
BIOLOGICAL EVALUATION OF SMALL MOLECULES THAT RESTORE  
E-CADHERIN EXPRESSION 
 
Introduction

 
 
The majority of human cancers arise from epithelial cells, which are held together 
through junction structures: tight junctions, adherens junctions, and desmosomes [1]. 
There are several classes of cell adhesion molecules, including cadherins, 
immunoglobulin-like cell adhesion molecules (Ig-CAMs), the hyluronan receptor CD44, 
and integrins [2] . The development of malignant tumors, in particular the transition from 
benign growths to more invasive or metastatic cancer, is often characterized by a tumor 
cell’s ability to overcome cell-to-cell adhesion and to invade the surrounding tissue, 
lymph system, and the circulatory system.  During the transition from a normal epithelial 
cell to a malignant (mesenchymal-like) cell, expression of some of these junction 
molecules is drastically reduced or terminal.  This is often referred to as the epithelial-to-
mesenchymal (EMT) transition, and is believed to play a prominent role in invasion, 
extravasion, and colonization during metastasis [3]. 
                                                        

Parts of Chapter 3 referenced from a publication: Sydney L. Stoops, A. Scott Pearson, Connie Weaver, 
Alex G. Waterson, Emily Days, Chris Farmer, Suzanne Brady, C. David Weaver, R. Daniel Beauchamp, 
Craig W. Lindsley. ‘Identification and Optimization of Small Molecules that Restore E-cadherin 
Expression and Reduce Invasion in Colorectal Carcinoma Cells’. ACS Chemical Biology. May 20 2011, 
6(5): 452-65 
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Cell-adhesion molecules are implicated in human carcinogenesis, and recently 
much attention has been directed towards E-cadherin [2].
 
 E-cadherin is a single-spanning 
transmembrane domain protein that forms homodimers at the cell surface membrane and 
interacts with the corresponding E-cadherin homodimers of neighboring cells (Figure 1).  
Aside from cell-to-cell adhesion, E-cadherin is a key component in cell polarity induction 
and epithelium organization.  The loss of E-cadherin function elicits active signals that 
support tumor-cell migration, invasion, and metastatic dissemination [4, 5]. 
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Figure 1. E-cadherin is a single-transmembrane spanning molecule that forms homodimers at 
the cellular membrane and interacts in a zipper-like manner with homodimers on neighboring 
cellular membranes.  The cytoplasmic cell-adhesion complex of E-cadherin consists of p120, β-
catenin, and α-catenin, which links E-cadherin homodimers to the actin cytoskeleton.  These 
interactions aid in cell polarity induction and epithelium organization.  Loss of E-cadherin leads to 
disassembly of the cytoplasmic cell-adhesion complex and release of p120, β-catenin, and α-
catenin, into the cytoplasm.  There are two pathways for the β-catenin protein to take once 
released into the cytoplasm. First, β-catenin can be sequestered by the APC/GSK-3β complex 
and ultimately tagged for proteosomal degradation via ubiquitination.  Second, upon activation of 
the Wnt signaling pathway or mutation in the APC/GSK3β complex, β-catenin can no longer be 
phosphorylated, and tagged for degradation; and therefore is translocated to the nucleus where 
together with TCF/Lef1 transcription factor it modulates the expression of target genes.  These 
genes are known to be involved in cell proliferation and tumor progression (Abbreviated from 
Chapter 1, Figure 4). 
 
 
The loss of E-cadherin function during tumor progression can be caused by 
genetic or epigenetic mechanisms, the most common of which is down regulation at the 
transcriptional level.  Repressor transcription factors Snail, Slug, and SIP1, as well as the 
helix-loop-helix transcription factor E12/E47, have been found to bind to the E2 boxes in 
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the promoter region of the E-cadherin gene and actively repress its transcription. DNase I 
hypersensitive site mapping indicated the loss of transcription factor binding, resulting in 
chromatin rearrangement in the regulatory region of the E-cadherin gene.  As a direct 
consequence of transcriptional inactivation, the E-cadherin locus is epigenetically 
silenced by hypermethylation and deacetylation [6-10]. It was shown through cloning and 
sequencing of the E-cadherin gene promoter that CpG methylation around the promoter 
region of the E-cadherin gene was present in cell lines that lacked E-cadherin expression 
and that E-cadherin could be restored in these cell lines upon treatment with the DNA 
methyltransferase inhibitor 5-azacytidine [11, 12]. Deacetylation of histone lysine 
residues by histone deacetylase (HDAC) enzymes results in chromatin compaction and 
inactivation of genes.  Deacetylation has been shown to occur around the E-cadherin gene 
promoter region by a repressor complex comprised of Snail, HDAC1, and HDAC2.  It 
has been shown that Snail preferentially binds the E2 box in the promoter region, while 
binding directly to HDAC2 and indirectly to HDAC1.  Treatment of cell lines that have 
reduced E-cadherin expression with Trichostatin A (TSA), a histone deacetylase 
inhibitor, leads to restored expression of E-cadherin [13, 14]. 
As reported in Chapter 2, we developed and used a high-throughput screen to 
discover lead compounds that restored E-cadherin expression in a metastatic colon 
adenocarcinoma cell line, SW620, which exhibited low levels of E-cadherin expression.  
We were able to develop preliminary structure-activity relationships (SAR) around the 
lead compound 1 using a Western blot-based E-cadherin restoration assay to screen 
analogs.  In addition, we were able to develop an In Cell Western (ICW) assay with the 
Odyssey Imaging System.  Within this chapter we will discuss use of the ICW to quantify 
 70 
EC50 values for selected active compounds.  Additionally, we were able to confirm E-
cadherin restoration via visualization of E-cadherin and β-catenin at the membrane after 
treatment with profiled compounds. The compounds reduced the invasion of colon cancer 
cells (SW620) and lung cancer cells (H520) with minimal effects on cellular 
proliferation.  Finally, we show that the compounds increase acetylation of the H4 
histone, but do not appear to function via HDAC inhibition, leading to a preliminary 
high-throughput attempt at identifying the molecular target through submitting selected 
analogs for outsourced screening. 
 
Methods and Materials 
 
Cell Culture 
 A colorectal adenocarcinoma cell line, SW620, and a squamous cell lung carcinoma cell 
line, H520, were obtained from the American Type Culture Collection (Manassas, VA) 
and maintained in a humidified atmosphere of 5% CO2 in air at 37 °C.  The cells were 
routinely cultured in RPMI 1640 supplemented medium with 10% fetal bovine serum 
(Atlanta Biologicals, GA) and 100 μg/mL penicillin-streptomycin.   
Protein Expression – Western Blot Analysis 
 SW620 and H520 cells (7.5 x 10
5
/mL) were seeded in 6 cm round plate 24 hours 
prior to treatment. Cells were treated with a 10 μM concentration of synthesized 
compound for 24 hours in RPMI 1640 supplemented medium and 100 μg/mL penicillin-
streptomycin. Total protein was isolated from cells with the use of RIPA lysis buffer with 
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protease inhibitors in order to determine E-cadherin protein expression levels.  The 
complete protocol can be referred to in the Methods & Materials section of Chapter 2.  
Protein Expression – In Cell Western Analysis 
 SW620 and H520 cells (10 x 10
4/100 μL) were seeded in a 96-well plate prior to 
treatment. Cells were treated with a 10 μM concentration of synthesized compound in 
quadruplicate for 24 hours in RPMI 1640 supplemented medium and 100 μg/mL 
penicillin-streptomycin.  The complete protocol can be referred to in the Methods & 
Materials section of Chapter 2. 
Immunofluorescence Analysis and Deconvolution Microscopy  
SW620 and H520 cells (7 x 10
4
/well) were seeded on 8-well chamber slides for 
24 hours prior to treatment.  Cells were treated with 10 μM concentration of synthesized 
compound for 24 hours in RPMI 1640 supplemented medium and 100 μg/mL penicillin-
streptomycin.  The cells were rinsed with PBS and fixed with 100% methanol for 15 
minutes at 4 °C.  The cells were rinsed with PBS and blocked and permeabilized with 2% 
BSA and 0.2% Triton X-100 in PBS.  The cells were then incubated with the following 
primary antibodies: anti-β-catenin and anti-E-cadherin diluted in 1% BSA in PBS 
blocking solution overnight at 4 °C.  After 3 washes with PBS, the cells were incubated 
with appropriate secondary antibodies conjugated to Fluorescein (1:200; Sigma, St. 
Louis, MO), Texas Red (1:500; Invitrogen, Carlsbad, CA), and DAPI (1:2000, Sigma, St. 
Louis, MO) for 40 minutes at room temperature.  The cells were washed 3 times with 
PBS, and then mounted with Vectashield mounting medium (Vector Laboratories, 
Burlingame, CA).  Deconvolution microscopy analyses were performed using the 
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DeltaVision
®
 Core (Applied Precision) microscope.  All images were taken using a 600x 
oil immersion objective and converted to a TIFF format and arranged using Photoshop 
7.0 (Adobe, Seattle, WA). 
Viability Assay 
 SW620 and H520 cells (2.5 x 10
4/100 μL) were seeded in 96-well microtiter 
plates prior to treatment. Cells were treated with 10 μM concentration of synthesized 
compound in quadruplicate for 24 hours and 48 hours in RPMI 1640 supplemented 
medium and 100 μg/mL penicillin-streptomycin.  The Quick Cell Proliferation Assay Kit 
from BioVision (Mountain View, CA) was used to measure proliferation.  The RPMI 
media was removed and replaced with 100 μL of the WST-1/ECS reagent diluted 1:10 in 
RPMI supplemented medium.  The plates were incubated for 1 hour in an incubator with 
5% CO2 in air at 37 °C.  The change in proliferation was quantified by measuring the 
absorbance of the dye solution at 450 nm on a microtiter plate reader. 
Proliferation Analysis 
 SW620 and H520 cells (2.5 x 10
4
/100 μL) were seeded in 96-well microtiter 
plates prior to treatment. Cells were treated with a 10 μM concentration of selected 
compounds in triplicate for 48 hours in RPMI 1640 supplemented medium and 100 μg/ml 
penicillin-streptomycin.  The CycLex
®
 Cellular BrdU ELISA Kit from MBL 
International (Woburn, MA) was used to measure proliferation.  The RPMI medium was 
removed and replaced with 100 μL of 1x BrdU label mix in RPMI medium for 2 hours at 
37 °C in 5% CO2 in the air. The BrdU label mix was removed and 200 μL of the 
Fix/Denature solution was added and incubated for 30 minutes at room temperature.  The 
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plate was drained, incubated with 50 μL of primary antibody for 1 hour at room 
temperature, rinsed with wash buffer, and incubated with 50 μL of secondary antibody.  
The wells were rinsed with wash buffer followed by a single rinse with PBS and drained.  
50 μL of substrate solution was added and incubated for 6 minutes followed immediately 
by 50 μL of Stop solution.  The change in proliferation was quantified by measuring the 
absorbance of the dye solution at 450 nm on a microtiter plate reader. 
Invasion Analysis 
 SW620 or H520 cells (2.5 x 10
5
/mL) were seeded in 6-well plates prior to 
treatment. Cells were treated with a 10 μM concentration of synthesized compound for 24 
hours in RPMI 1640 supplemented medium and 100 μg/mL penicillin-streptomycin.  40 
μL (2.5 mg/mL) of BD Matrigel Basement Membrane Matrix (BD Biosciences, Bedford, 
MA) was added to the top of the insert of a 24-well Transwell Permeable Support plate 
with a polycarbonate membrane with 8 μm pore size (Corning Inc, Corning, NY).  Then 
the cells were trypsinized and 3x10
5
/250 μL cells were added to the top of the chamber in 
serum-free RPMI medium, and 1 mL of RPMI medium with 10% FBS was added to the 
bottom of the well.  Then the plates were incubated for 72 hours at 37 °C in a humidified 
incubator with 5% CO2 in the air.  Then the wells were stained with 1% crystal violet in 
50% methanol for 1 hour and washed in PBS.  The membrane was cut off, adhered to a 
slide with glycerol, and analyzed in 20x field via microscopy.  3 – 20x fields were 
quantified per membrane.  
 Cell viability of the remaining cells plated in the top chamber was observed using 
Calcein AM.  The media was carefully removed from the top chamber, 1 μM 
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concentration of Calcein AM in RPMI medium (100 μL) was added to each well, and the 
plate was incubated for 1 hour at 37 °C in a humidified incubator with 5% CO2 in the air.  
Calcein staining of viable cells was observed and captured at 200x using a fluorescence 
microscope.   
RNA-Seq Experiment and Analysis 
 The RNA-Seq experiments and analyses were carried out at HudsonAlpha 
Institute for Biotechnology (Huntsville, AL).  SW620 cells (1.5 x 10
6
/1 mL) were seeded 
in 3.5 cm dish; 9 total.  3 plates were treated with a 10 μM concentration of DMSO, 
compound 1, or compound 57 for 24 hours in RPMI 1640 supplemented medium and 100 
μg/mL penicillin-streptomycin.  RNA was extracted from each of the samples and 
quantified prior to shipment to HudsonAlpha.  Upon arrival, the 3 samples per treatment 
were pooled and prepared for sequencing.  Raw data was aligned using Tophat and then 
analyzed through the Cufflinks pipeline on site. 
Histone Acetylation Anaylsis 
 SW620 and H520 cells (7.5 x 10
5
/mL) were seeded in 6 cm round plates prior to 
treatment. Cells were treated with a 10 μM concentration of synthesized compound for 24 
hours in RPMI 1640 supplemented medium and 100 μg/mL penicillin-streptomycin.  The 
Nuclear Extract Kit from Active Motif (Carlsbad, CA) was used to collect the nuclear 
fraction from each sample. 20 μg of proteins were loaded per sample onto 10% SDS-
polyacrylamide gels that were run at 100V for approximately 1.5 hours.  The Western 
blot protocol is same as previous described in the ‘Protein Expression – Western Blot 
Analysis’ section.  To determine Histone H4 acetylation, the membrane was incubated 
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with the Acetyl-Histone H4 antibody (1:1000; Millipore, Temecula, CA) in 10 mL
 
LI-
COR blocking buffer (1:1 dilution in PBS) overnight at 4 °C. The next day, the antiserum
 
was removed and the membrane was washed in PBS-T before addition of secondary 
antibody: IRDye 800-conjugated goat anti-rabbit IgG (1:10,000) in
 
10 mL LI-COR 
blocking buffer (1:1 dilution in PBS) for 1 hour at
 
room temperature. The membrane was 
washed in PBS-T and analyzed on the Odyssey
 
IR imaging system.  Membranes were 
stripped with 10 mL of LI-COR stripping buffer (1:5 dilution in ddH20) for 30 minutes at 
room temperature with gentle agitation followed by 3 ten-minute washes with PBS.  
Membranes were re-probed with anti-Histone H4 Pan-acetylation (1:1000; Upstate, Lake 
Placid, NY), anti-RhoGDIα (1:1000; Santa Cruz Biotechnologies, Santa Cruz, CA), and 
anti-PARP 1/2 (1:1000; Santa Cruz Biotechnologies, Santa Cruz, CA) in 10mL of LI-
COR blocking buffer (1:1 dilution in PBS) for 1 hour at room temperature. The antiserum
 
was removed and the membrane was washed 3 times in PBS-T before addition of 
secondary antibody: IRDye 700-conjugated goat anti-rabbit IgG (1:10,000) in
 
10 mL LI-
COR blocking buffer (1:1 dilution in PBS) for 1 hour at
 
room temperature. At the end of 
the incubation period, membranes
 
were washed 3 times with PBS-T and analyzed on the 
Odyssey
 
IR Imaging System. 
Statistical Analysis.  
 GraphPad Prism Software (GraphPad Software, San Diego, CA, USA) was used 
to analyze all data. 
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Results 
 
Visualization of E-cadherin Restoration by Selected Analogs 
As mentioned previously, all compounds were screened by Western blot to 
measure their ability to restore E-cadherin expression in the SW620 cells.  Compounds 
that restored E-cadherin to a similar or greater level than compound 1 were further 
screened in the same E-cadherin assay format in the H520 cell line.  Four compounds, 54, 
57, 73, and 116 were chosen for further profiling based on their performance in the E-
cadherin restoration assays and their structural variability.  Additionally, compound 140 
was utilized as a negative control since it does not restore E-cadherin expression in either 
the SW620 or H520 cell lines (Figure 2).   
 
 
 
 
Figure 2. Compounds selected for further profiling. 
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Figure 3A shows the ability of these compounds to restore E-cadherin in both the 
SW620 and H520 cell lines at a 10 μM concentration. It can be seen that the compounds 
display improved E-cadherin restoration compared to 1 and show slight variability 
between the two cell lines.   
As mentioned in Chapter 2, we wanted to develop a method that would facilitate 
the generation of concentration response curves and quantify EC50 values for restored E-
cadherin expression.  For this, we developed and utilized an ICW assay using the 
Odyssey Imaging System, which would allow for quadruplicate replicates for each 
concentration and direct quantification of the intensity of fluorescent secondary antibody 
within each well (Figure 3B).  Use of the ICW assay also allowed for fixation, staining, 
and analysis of the compound treatments in a single day, approximately 3 hours, as 
opposed to an overnight incubation with primary antibody necessary with the Western 
blot. Preliminarily, an optimized single point, 10 μM concentration, ICW assay was 
developed and the data for the profiled compounds in both the SW620 and H520 cell 
lines can be seen in Figure 3B.   
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Figure 3. Western blot (A) and ICW (B) data for profiled compounds. Cells were treated for 24 
hours with a single point 10 μM treatment prior to the assay.  Samples were probed for E-
cadherin and Tubulin (control) and secondary antibody fluorescence intensity was measured 
using the Odyssey Imaging System.  Fold change was calculated by normalizing all samples to 
the DMSO control at 1. 
 
 
The ICW assay appeared to trend with the western blot assay data, confirming 
that it could be utilized for the development of concentration response curves (CRC) 
based on E-cadherin restoration (Figure 3).  Representative curves can be seen in Figure 
4 for compound 1, compound 57, and compound 289 in both the SW620 and H520 cells.  
All EC50 values for selected active analogs screened can be seen in Appendix 1, Table 21.  
The EC50 values for 1, 57, and 293 in the SW620 cell line were 10.6 μM, 2.13 μM, and 
1.1 μM, and 5.3 μM, 1.25 μM, and 1.0 μM in the H520 cell line, respectively (Figure 4).  
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Figure 4. Concentration response curves for selected analogs. SW620 and H520 cells were 
treated for 24 hours with compound.  Concentration response curves were developed from 7 
treatment concentrations from 30 μM to 0.1 μM using the In-Cell Western assay.  Each 
concentration was tested in triplicate and plotted as the relative intensity of fluorescence; EC50 
values were determined and are shown below each graph.  The chemical structure is also shown 
to the right side of the figure for each profiled compound to display structural variability. 
 
 
 While we were able to quantify that a subset of selected compound 1 analogs 
were restoring E-cadherin, we also wanted to determine the localization of the E-cadherin 
protein within the cell.  For this, we used immunofluorescent microscopy to visualize the 
localization of E-cadherin and β-catenin in SW620 cells after treatment with the profiled 
compounds or DMSO (Figure 5).  E-cadherin is not present and β-catenin appears 
dispersed throughout the cytoplasm in the DMSO control and compound 140, an inactive 
analog, treated cells.  β-catenin dispersal throughout the cytoplasm was suspected in such 
treatments since E-cadherin was not present to sequester β-catenin to the member via 
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CCC formation. In Addition, the cells treated with active analogs displayed localization 
of both E-cadherin and β-catenin to the membrane, especially where cell-to-cell contact 
was made.  If E-cadherin was being restored to the membrane, as was observed via 
immunofluorescent microscopy, it is logical to hypothesize that β-catentin would be 
sequestered back to the membrane.  Co-localization of these proteins can be seen when 
the images are merged.  This suggests that our compounds are not only capable of 
restoring E-cadherin protein expression, but E-cadherin is a also successfully being 
transported to the membrane.  Additionally, the localization of E-cadherin and β-catenin 
to the membrane suggests that the E-cadherin cytoplasmic cell-adhesion complex is being 
restored at the membrane on the intracellular portion of the E-cadherin protein. 
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Figure 5.  Visualization of E-Cadherin localization.  SW620 cells were treated for 24 hours with a 
10 μM concentration of compound.  Each panel of three images represents a single treatment 
with immunofluorescent localization of E-cadherin or β-catenin as well as the merged image.  
Cells were viewed with 600x total magnification. 
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Having shown that the E-cadherin protein is being restored (Figure 3) and that 
the protein is localizing to the membrane in cells treated with active compounds (Figure 
5), we wanted to identify if the restoration was occurring at the transcriptional level.  For 
this we used primers for the E-cadherin mRNA transcript and PCR to determine if there 
were changes in mRNA levels after treatment of SW620 cells with DMSO, compound 1, 
compound 57, or compound 140.  We saw that treatment with compound 1 and 57 
resulted in a modest increase in E-cadherin mRNA transcripts as compared to the DMSO 
and 140 treated samples (data not shown).  In extension of this finding we decided to 
send 3 samples to HudsonAlpha Institute for Biotechnology for RNA-Seq analysis.  
RNA-Seq analysis, much like PCR, involves reverse transcription of mRNA samples into 
cDNA, which is then sequenced.  This provides a very detailed view of both the exact 
sequence of the genes expressed and the magnitude of the expression.  An example can 
be seen in Figure 6 in which the CDH1 gene reads are shown for each of the three 
treatments.  After analysis, cells treated with compound 1 had a 1.46 fold increase in E-
cadherin expression and cells treated with compound 57 had a 10.22 fold increase in E-
cadherin expression when compared to DMSO treated sample.  This data further 
validates that the compounds are restoring E-cadherin protein by enhancing the 
transcription of CHD1 gene.   
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Figure 6. Quantification of mRNA transcript levels after treatment of SW620 cells with selected 
analogs.  RNA-Seq experiments and data analyses were conducted at HudsonAlpha Institute for 
Biotechnology.  The panel shows the CDH1 (E-cadherin gene) expression for DMSO, compound 
1, and compound 57 treated samples.  Reads are in bright blue and the grayish blue boxes 
between the reads show junctions between exons. 
 
 
 It became apparent within the first initial libraries that a distinct morphological 
change was occurring in the SW620 cells that were treated with active compounds 
(Figure 7A).  Thus, we could identify prior to the Western blot or ICW assay if the 
compounds were likely to be active or inactive.  It became apparent that the compounds 
that elicited a greater fold increase in E-cadherin expression also had a larger percentage 
of cells within the well that appeared to have undergone this distinct morphology change.  
The SW620 cells typically have a spherical shape, as seen in the DMSO and compound 
140 treated cells in Figure 7A.  The cells treated with active compounds, as seen in the 
compound 1 and compound 57 treated cells, appear to have spread out in all directions.  
Curious about this morphology change, we plated SW620 cells in an E-plate, which 
allowed us to measure changes in cell index using the xCelligence System by Roche 
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Diagnostics.  Cell index is a reflection of cell attachment, number, and morphology of 
cells within the well.  After a 10 μM treatment we observed the cells for 50 hours; the 
cells were treated a second time after 24 hours.   It can be seen that the cells treated with 
the active compounds have an increased cell index as compared to cells treated with 
DMSO or inactive analogs  (Figure 7B).  This suggests that the compounds have 
improved adherence to the bottom of the E-plate after treatment with the active 
compounds, which may explain the morphology changes seen in Figure 7A.  One could 
hypothesize that the increase in cell index observed after treatment with active analogs 
was a result of E-cadherin restoration to the membrane leading to functional assembly of 
additional adhesion complexes [15, 16]. In addition, this would result in CCC formation 
on the intracellular portion that mediates the association and stability with the actin 
cytoskeleton [17-19]. 
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Figure 7.  Distinct changes in cell morphology in the SW620 cells were observed after treatment 
with selected analogs.  (A) Pictures acquired at 20x using a basic light microscope (B) Cell Index 
data collected from the xCelligence machine over 50 hours and legend indicating the 10 μM 
treatment of selected analogs per colored line. 
 
 
 
Cells Remain Viable and Invasion is Inhibited after Treatment by Selected Analogs 
Next we wanted to look at viability of the SW620 and H520 cells after 48 hours 
of treatment with profiled analogs.  This was conducted using the WST-1 reagent, which 
is cleaved in metabolically active cells to produce a soluble substrate whose absorbance 
can be measured.  Overall, the active analogs had no effect on cell viability in either cell 
line with exception to compound 57.  Compound 57 displayed a moderate decrease of 
cell viability in both the SW620 and H520 cell lines (Figure 8A). 
Additionally, we wanted to determine if the compounds were capable of 
inhibiting cell proliferation, as uncontrolled proliferation is common in carcinogenesis.  
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For this we utilized a standard bromodeoxyuridine (BrdU) incorporation assay to 
determine if the compound treatments were inhibiting DNA synthesis.  Compound 57 
displayed significant inhibition of proliferation, while compounds 116 and 73 displayed 
moderate inhibition in the SW620 cells.  However, only 57 and 73 showed moderate 
inhibition in the H520 cells (Figure 8B).  Overall, compound 57 is the only profiled 
analog that displays significant effects by decreasing both cell viability and proliferation 
in both the SW620 and H520 cell lines.  
 
 
 
Figure 8.  Compounds have minimal effect on viability (A) and proliferation (B).  (A) In the viability 
assay, SW620 or H520 cells were treated for 48 hours with a 10 μM concentration of compound 
then analyzed by the WST-1 assay.  (B) In the proliferation assay, SW620 or H520 cells were 
treated for 48 hours with a 10 μM concentration of compound then analyzed by the BrdU 
incorporation assay.  For both experiments each treatment was performed in triplicate, and 
absorbance was measured at 450 nm.  
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In addition, we wanted to confirm that the compounds were not cytotoxic to a 
normal epithelial cell line.    We screened the MCF10A cell line, a normal-like mammary 
epithelial cell line, in both the viability (WST-1) and proliferation (Brd-U) assays after 
treatment with the profiled compounds for 48 hours (Figure 9).  There were no 
significant decreases in viability or proliferation after treatment with active compounds, 
suggesting that these compounds are not cytotoxic to normal epithelial cells.   
 
 
 
Figure 9. Compounds are not cytotoxic to MCF10A cells – a normal-like human mammary 
epithelial cell line.  (A) In the viability assay, cells were treated for 48 hours with a 10 μM 
concentration of compound then analyzed by the WST-1 assay.  (B) In the proliferation assay, 
cells were treated for 48 hours with a 10 μM concentration of compound then analyzed by the 
BrdU Incorporation Assay.  For both experiments each treatment was performed in triplicate, and 
absorbance was measured at 450 nm. 
 
 
Further, we sent compounds 1 and 57 to be screened in a 60 cancer cell line panel 
at the National Cancer Institute (NCI).  The panel of cancer cell lines represented 
leukemia, melanoma, lung, colon, brain, ovary, breast, prostate, and kidney cancers.  The 
compounds were screened initially at a single 10 μM concentration in all 60 cancer cell 
lines to look at growth inhibition.  There were only a few cell lines that displayed a 
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moderate amount of growth inhibition after either treatment.  Compound 1 showed 
moderate growth inhibition against the PC-3, A498, and UACC-257 cell lines (Table 1).  
Compound 57 showed moderate growth inhibition against the RPMI-8226, NCI-H522, 
HCC-2996, MALME-3M, SK-MEL-28, UACC-257, OVCAR-4, OVCAR-8, NCI/ADR-
RES, A498, PC-3, MCF-7, T-47D, and MDB-MB-468 cell lines (Table 2).  While there 
was moderate growth inhibition in selected cell lines there wasn’t any significant growth 
inhibition, thus the compounds were not screened in a dose response manner.  However, 
it did provide additional cell lines that could be pursued in the future if necessary in order 
to validate the mechanism of action. 
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Table 1.  NCI Cytotoxicity Screen for Compound 1. 
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Table 2. NCI Cytotoxicity Screen for Compound 57. 
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Since E-cadherin expression is down regulated at the invasive front in a variety of 
cancers, it was important to determine if compound 1 and selected analogs reduced 
invasion in the SW620 and H520 cell lines [18, 20, 21].  The cells were treated with a 10 
μM concentration of profiled compounds for 24 hours and then allowed 72 hours to 
invade through a matrigel-covered chamber.  In our preliminary analyses of invasion we 
fixed and stained the membranes with 1% crystal violet and counted the cells within a 
20x field under the microscope.  We saw that compound 1 and the profiled compounds 
all reduced invasion in both the SW620 and H520 cells (Figure 10A).   Specifically, 
compounds 57 and 73 had the most significant effect on reducing invasion of the SW620 
and H520 cells through the matrigel.  However, there was some concern as both of these 
compounds were seen to reduce proliferation in both the SW620 and H520 cells.  
Therefore, we had to question if the reduction in invasion was a result of reduced cell 
proliferation or viability, since the cells were allowed to invade for 72 hours, or because 
the compounds do reduce invasion separate from decreasing cellular proliferation.  
To test this, Calcein AM was used to stain the cells on both the top and bottom of 
the chamber.  A fluoroblok membrane within the chamber inserts allowed for 
fluorescence to be read on either side of the chamber without interference.   This will 
account for any inhibition of proliferation, as seen in Figure 8A, as the experiments can 
be normalized to the number of cells remaining in the top chamber.  This also confirms 
that treatment with the compounds is not cytotoxic as Calcein AM is converted to its 
fluorescent form (Calcein) by living cells.  As seen in Figure 10B the compounds were 
able to reduce the number of invading cells compared to the DMSO control in the SW620 
cells as well as the H520 cells (data not shown).  Additionally, the inactive analog, 140, 
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did not reduce invasion, as the fold change was similar to the DMSO negative control. 
This suggests that the decrease in invasion observed with compound treatment alterations 
is not likely to be due to cytotoxicity or inhibition of proliferation, but a result of 
molecular effects of the compound on the cells. 
 
 
 
Figure 10. Profiled compounds reduced invasion in both the SW620 and H520 cells. (A) SW620 
or H520 cells were treated for 24 hours with a 10 μM concentration of compound and then plated 
in a matrigel covered Boyden invasion chamber.  Cells were given 72 hours to invade, were 
strained with crystal violet, and then counted. 3 - 20x fields per membrane, 3 membranes per 
treatment. (B) SW620 cells were treated for 24 hours with a 10 μM concentration of compound 
and then plated in the matrigel-covered invasion chamber.  Cells were given 72 hours to invade, 
were strained with Calcein AM, and then counted on a fluorometer. A fold change of invading 
cells was calculated as normalized to the DMSO control.  
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Increase in Histone Acetylation After Treatment with Active Compounds 
 We used our knowledge of TSA, a known HDAC inhibitor and our high-
throughput screen positive control, to hypothesize that the compounds may be altering 
histone acetylation and therefore restoring E-cadherin expression.  It has been shown that 
histone deacetylation may lead to transcriptional repression of a gene.  More specifically 
the HDAC1/2-Snail complex has been shown in several cancer models to repress E-
cadherin expression directly [14, 22, 23].  Thus, we treated SW620 and H520 cells with 
selected compounds and used a Western blot assay to probe for Histone H4 pan-
acetylation in addition to total H4 histone present in each sample.  Figure 11 shows the 
data expressed as the percent change in histone acetylation above a DMSO control.  The 
cells treated with active compounds shown to restore E-cadherin had a marked increase 
in histone acetylation compared to the DMSO control and 140, the negative analog. 
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Figure 11. Compounds increased Histone H4 pan-acetylation.  SW620 or H520 cells 
were treated for 24 hours with a 10 μM concentration of compound. Nuclear fractions 
were isolated and subjected to western blot analysis.  Samples were probed for Histone 
H4 acetylation and total Histone H4. Values were quantified as the fold change in histone 
acetylation above the DMSO control.  The blot was also probed with Parp1/2 and 
RhoGDI to confirm clean fractionation for each sample (not shown). 
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Preliminary Efforts to Identify the Molecular Target via Outsourced Screens 
Several analogs of compound 1 were profiled in screening assays, both general 
and specific protein family screens, in an attempt to identify the molecular target.  A 
preliminary screen of one analog, compound 80, was evaluated in the MDS Pharma Lead 
Profiling radioligand binding screen, which consists of a panel of 68 GPCRs, ion 
channels, transporter and nuclear hormone receptors.  Compound 80 displayed no 
significant activity (<50% inhibition at 10 M), with the lone exception of activity at the 
imidazoline I2 central receptor (Table 3).  The data indicated that the compounds 
discovered in this project are not broadly promiscuous.  A more specific screen was 
conducted at MDS Pharma Services against a set of potential targets that might be of 
importance for epigenetic regulation, such as the sirtuins and matrix metalloproteases 
(MMP).  However, no significant activity was found for the compounds at 10 μM against 
the sirtuins, nine MMP isoforms, catechol-O-methyl transferase, or histamine N-
methyltransferase.   
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Table 3. MDS Pharma Lead Profiling results for Compound 80. 
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 Based on published work concerning the involvement of HDAC’s in E-cadherin 
repression and cancer and our visualization of increased histone acetylation by treatment 
with our compounds, we elected to test two compounds, 32 and 70, for direct inhibition 
of HDAC isoforms, using commercially available assays measuring direct inhibition of 
HDACs 1-11 at Research Biology Corporation.  Neither analog showed direct inhibition 
against any of the HDAC proteins in the screen.  From this we were able to conclude that 
while our compounds alter histone acetylation, which may explain the restoration of E-
cadherin expression, unlikely to be a result of the direct inhibition of the HDAC proteins.   
However, this does leave a variety of potential molecular targets such as histone 
acetyltransferase (HAT) as well as repressor transcription factors, such as Snail, which 
are known to complex with HDACs. 
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Discussion 
 
 Here we report that the restoration of E-cadherin protein within the cells as a 
consequence of cell treatment with active analogs (54, 57, 73, 116) is being localized to 
the membrane.  Co-localization with β-catenin at the membrane, as seen in the 
immunofluorescent microscopy analysis, would suggest that the E-cadherin complex is 
being restored at the membrane (although complex function was not tested).  These data 
further validate the success of the phenotypic high-throughput screen that was utilized to 
identify compound 1.  In addition, a distinct morphological change was observed in the 
SW620 cells after treatment with active compounds during the western blot and ICW 
screening assays.  The cells appear to be changing from a small spherical morphology to 
a more flattened and spread out morphology.  This information, coupled with the increase 
in cell index observed in cells treated with active compounds, suggests that the 
restoration in E-cadherin may be playing a role in the cells flattening out and adhering 
better to the bottom of the plate or well.   
Additionally, we undertook the biological evaluation of compound 1 and selected 
analogs in a variety of assays in an effort to better understand how these compounds are 
affecting the function of the cell aside from restoring E-cadherin expression.  The 
profiled compounds had minimal effect on viability and proliferation, with exception to 
compound 57, in both the SW620 and H520 cells.  Unfortunately, further analysis of two 
compounds in a 60 cancer cell line panel at NCI did not identify any specific cancer types 
that were sensitive to a single point 10 μM treatment.  While this is disappointing, it still 
leaves the possibility for the compounds being used in combination with more aggressive 
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treatments to induce a synergistic effect.  This would ideally allow for a sub-therapeutic 
dose of a more cytotoxic therapy (with severe side effects), allowing for a more enhanced 
targeted response at the tumor, but fewer debilitating side effects. 
 Finally, in regards to our preliminary efforts to identify the molecular target, we 
received a lot of negative data.  Due to the small size and low molecular weight of these 
molecules our first thought was that they would be extremely promiscuous and bind to a 
wide array of intracellular proteins and membrane channels and receptors rendering the 
molecular target impossible to elucidate.  However, from the MDS Pharma general 
radioligand panel screen we learned that these small molecules are very clean.  Many of 
the targets within the MDS Pharma general panel screen elicit adverse events and are 
often avoided during drug development efforts.  Therefore, it is excellent that our 
molecules are clean both from target identification and drug development stand points.  
Additionally, it was surprising to learn that the compounds were not HDAC 
inhibitors.  Due to known information of HDAC inhibitors restoring E-cadherin 
expression (ie. TSA, our positive control) and similarities between our analogs and 
known HDAC inhibitors there was high hope that a screen of HDAC isoforms would 
identify at least one target.  Further, HDAC inhibitors have been an area of focus in 
cancer therapeutic development, and specifically around developing isoform specific 
inhibitors.  Identifying a selective HDAC inhibitor would have quickly moved the project 
forward; although now we believe we may have a potentially novel target and mechanism 
of action.  Therefore, this data led us to believe that there may be a single molecular 
target, and that understanding the mechanism of action and ultimately identifying the 
molecular target were the next questions to address.  
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CHAPTER IV 
 
UNDERSTANDING THE MECHANISM OF ACTION OF SMALL MOLECULES 
THAT RESTORE E-CADHERIN EXPRESSION 
 
Introduction 
 
 The major disadvantage to running a high-throughput screen using a phenotypic 
assay to identify lead compounds, is that the mechanism of action, and more specifically 
the molecular target, remain unknown.  As noted in Chapter 3, we were able to synthesize 
small molecules that restored E-cadherin expression in both a colorectal and lung cancer 
cell lines, which had a repressed but functional CDH1 gene.  In Chapter 2, it was noted 
that the SAR surrounding the original screening hit, compound 1, was shallow with 
activity lost from subtle changes made to the molecule.  While in more recently 
synthesized libraries, we were able to install a carbon linker tethered by amines on either 
side allowing for the molecule to be homologated with good activity; we are hindered by 
not knowing the molecule target in more aggressively pursing SAR.  
 Loss of E-cadherin protein expression is frequently found during tumor 
progression and has been identified as a clinical marker for poor prognosis in some 
cancers [1-3].  E-cadherin expression can be regulated at the transcriptional level as well 
as the post-translational level.  Based on preliminary data, histone acetylation, and 
RNASeq data provided in Chapter 3 we focused our attention on regulation of E-cadherin 
expression at the transcriptional level.   
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 Silencing of E-cadherin at the transcriptional level is a result of repressor 
transcription factor binding complexes that bind to the promoter region of the CDH1 
gene.  These repressor transcription factors include Snail1 (Snail), Snail2 (Slug), ZEB1 
(δEF1), ZEB2 (Sip1), E47, and Twist [4].  Binding of these repressor transcription factors 
in complexes leads to epigenetic silencing of the CDH1 gene by histone modifications 
and DNA hypermethylation [5-7].  The process of silencing the E-cadherin gene 
promoter is a complex cascade of events that is still being identified; although there is a 
dynamic range of repression both reversible and irreversible.  Snail is first recruited and 
forms a complex with HDACs, thereby inducing histone deacetylation, while a second 
repressor complex is recruited to the site to promote histone methylation.  This 
preliminary repression can induce expression of additional repressor proteins, such as 
ZEB1, which bind to the CDH1 promoter further promoting E-cadherin gene silencing 
[1].   
  
Methods and Materials 
 
Cell Culture 
  A colorectal adenocarcinoma cell line, SW620, and a squamous cell lung 
carcinoma cell line, H520, were obtained from the American Type Culture Collection 
(Manassas, VA) and maintained in a humidified atmosphere of 5% CO2 in air at 37 °C.  
The cells were routinely cultured in RPMI 1640 supplemented medium with 10% fetal 
bovine serum (Atlanta Biologicals, GA) and 100 μg/mL penicillin-streptomycin.   
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Quantitative (q)PCR Analysis 
RNA extraction was performed using the RNEasy Mini Kit (Qiagen Corporation), 
following the manufacturer's protocol.  The Transcriptor Universal cDNA Master kit 
(Roche Diagnostics) was used for cDNA synthesis.  1.0 μg of RNA per sample was used 
for each reaction.  Samples were incubated at room temperature for 5 minutes, 55 °C for 
10 minutes, 85 °C for 5 minutes, on ice for 5 minutes, and then diluted to a total volume 
of 100 μL.  Real-time analysis was performed on the Light Cycler 480 (Roche 
Diagnostics) with Universal Probe Master system; primers and probes for CDH1, 
NFATc1, NFATc2, and PMM-1 genes were selected according to the Software Probe 
Finder (Roche Diagnostics).  The protocol consisted of 45 cycles: 10 seconds at 95 °C, 30 
seconds at 60 °C, and 1 second at 72 °C.   
 
 
Table 1. PCR Primers and UPL Probes for each gene analyzed. 
Gene Forward Primer Reverse Primer UPL Probe 
CDH1 5’- TTG ACG CCG AGA GCT ACA C -3’ 
5’- GTC GAC CGG TGC 
AAT CTT -3’ 80 
NFATc1 5’ - CCA AGG TCA TTT TCG TGG AG - 3’ 
5’- GGT CAG TTT TCG 
CTT CCA TC -3’ 45 
NFATc2 5’- CAT CTA ACC CCA TCG AGT GC -3’ 
5’- GCT GTC TGT GTC 
TTG TCT TTC AA -3’ 44 
PMM-1 5’- TTC TCC GAA CTG GAC AAG AAA -3’ 
5’- CTC TGT TTT CAG 
GGG TTC CA -3’ 7 
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Plasmid Constructs 
 The plasmids constructs were graciously provided from two separate labs.  The 
1.4 kbp E-cadherin promoter plasmid (E1) was synthesized in Eric R Fearon’s 
Laboratory at The University of Michigan [8].  The E-cadherin promoter plasmids E2-E8 
which ranged in size from 1.2 kbp to 100bp of the E-cadherin promoter were synthesized 
in Ju Hshiung Chen Laboratory at Tzu Chi University in Hualien, Taiwan [9].  All 
plasmid constructs were sequenced at the Vanderbilt University Sequencing Core to 
confirm the E-cadherin promoter fragments using the PCR primers listed below. 
 
Table 2.  PCR primers for Plasmid Construct E2 – E8 Sequencing 
E2 -995/135 (forward) 5‘-GGTACCGCCGCTCGAGCGAGAGTGCAGTGG-3’ 
E3 -833/135 (forward) 5’-GGTACCGCCTGTAGTCCCAGCTACTC-3’ 
E4 -677/135 (forward) 5’-GGTACCAAAAATTAGGCTGCTAGCTCAGTGG-3’ 
E5 -517/135 (forward) 5’-GGTACCTCTCTCTACAAAAAGGCAAAAGAAAA-3’ 
E6 -357/135 (forward) 5’-GGTACCGAAAGAGTGAGCCCCATCTCCAAAA-3’ 
E7 -195/135 (forward) 5’-GGTACCCACCTAGACCCTAGCAACTCCAGGCT-3’ 
E8 -38/135 (forward) 5’-GGTACCTCCGGGGCTCACCTGGCTGCAGCC-3’ 
 (Reverse) 5‘-AAGCTTCTGCGGCTCCAAGGGCCCATGGCTG-3’ 
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Transient Transfection Experiments  
Cells were plated 12–24 hours before transfection at 3-4x105 cells per well in a twenty-
four well plate. In all, 0.15 μg of various DNA constructs and 0.10 μg of β-galactosidase 
construct (Promega) were mixed with 75 μL of Effectene (Qiagen). The mixture was 
incubated at room temperature for 10 min. After washing the cells with 1x�PBS, the 
DNA/Effectene was added to serum free RPMI, transferred into the wells, and then 
incubated at 37 °C in a 5% CO2 humidified incubator for 4 hours. After the transfection 
incubation, the cells were washed with 1x�PBS and then treated with 10 μM treatment of 
DMSO, compound 1, or selected analogs in RPMI with 10% FBS for 24 hours. Each 
treatment was conducted in triplicate per plasmid construct.  At the end of the 24 hour 
incubation, the transfected cells were lysed with reporter lysis buffer (Promega).  
Luciferase and β-Galactosidase Reporter Assays 
 The enzymatic activity was measured for firefly luciferase using the Luciferase 
Assay System (Promega) with a luminometer. All luciferase assays were carried out in 
triplicate and experiments were carried out at least twice. 
 The enzymatic activity was measure for β-galactosidase using the β-Galactosidase 
Enzyme Assay System (Promega) with a spectrophotometer.  All β-galactosidase assays 
were carried out in triplicate and experiments were carried out at least twice. 
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Results 
 
Evaluation of Increase in E-Cadherin mRNA Transcript Levels 
 Our preliminary findings using standard PCR (data not shown) as well as the 
RNASeq analysis data (Chapter 3, Figure 6) showed that compound 1 and active analogs 
increased mRNA transcript levels in the SW620 cells.  We wanted to confirm our 
preliminary findings using RT-qPCR (Figure 1). Therefore, SW620 cells were treated 
with a 10 μM treatment of previously profiled compounds that had been screened in the 
biological assays presented in Chapter 2.  Compounds 1 and 73 had slight increases in 
mRNA transcription levels relative to DMSO; however, the remaining positive analogs 
screened showed at least a 10-fold increase in E-cadherin mRNA transcript levels 
(Figure 1A).    
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Figure 1. qPCR data for E-cadherin after a 10 μM treatment with selected compounds for 24 
hours.  (A) SW620 (B) E-cadherin mRNA transcript levels in both cell lines treated with more 
recently synthesized analogs.  All values normalized to the DMSO control and compounds 140 
and 290 are inactive analogs. 
 
 
Additionally, two of the newly synthesized analogs, represented in Figure 2, were 
analyzed as well in both the SW620 and H520 cells (Figure 1B).  In both cell lines, the 
active compound, 289, had a significant increase in E-cadherin mRNA transcript levels as 
compared to DMSO and the negative control, compound 290.  
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Figure 2.  Selected newly synthesized analog (289) with improved E-cadherin restoration and an 
inactive analog (290) 
 
 
 We were curious to identify a more specific time point in which activity of the 
active analogs occurs within the cell.   Until this point, we had been using a 24 hour 
treatment incubation time, which is a standard incubation time.  For the time course 
experiment, RNA was extracted from treated cells at 6 time points: 30 minutes, 1 hour, 3 
hours, 6 hours, 12 hours, and 16 hours.  A 24 hour time point was not done due to it being 
the standard incubation time used in all prior experiments and had already been 
conducted (Figure 1).   Result for RT-qPCR analysis of E-cadherin mRNA transcript 
levels at all 6 times points can be seen in Figure 3, in which the data is normalized to the 
DMSO control samples for each time point.   
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Figure 3. Time course experiment and concentration response curve looking at E-cadherin 
mRNA transcript levels via qPCR.  (A) SW620 cells were treated with a 10 μM concentration of 
selected analogs or DMSO.  RNA was extracted at 6 time points indicated above, and qPCR was 
run to analyze transcription levels of E-cadherin (N=3). (B) SW620 cells were treated with 7 
concentrations between 100 nM and 30 μM for 6 hours, RNA was extracted, and qPCR was turn 
to analyze transcription levels of E-cadherin. Samples were normalized to DMSO control and 
compound 290 is an inactive analog.     As can be seen in Figure 3 there is a 7.26-fold increase in E-cadherin mRNA 
transcript levels after 3 hours of treatment with compound 289.  However, at 6 hours, we 
see a drastic increase in E-cadherin mRNA transcript levels with treatment of compound 
289, a 24.22-fold increase as compared to DMSO control.  We were surprised to see that 
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compound 289 had an effect after only 6 hours, and that levels continued to increase 
through 16 hours of treatment; 53.40-fold increase after 12 hours and 58.68-fold increase 
after 16 hours of treatment.  I think the most notable bit of information from the time 
course experiment is the 7.26-fold increase in E-cadherin transcription levels at 3 hours.  
It would be interesting to further analyze the changes in transcription levels of E-cadherin 
between 1 – 3 hours to narrow down a point when E-cadherin mRNA transcript levels 
begin to increase. 
 Additionally, we developed a concentration response curve for E-cadherin mRNA 
transcript levels with various concentrations of compound 289 after 6 hours of 
incubation.  7 concentrations of compound 289 from 100 nM to 30 μM were used to treat 
the cells for 3 hours, RNA was extracted, and mRNA levels were quantified using qPCR.  
We saw that E-cadherin mRNA transcript levels begin to increase at 500 nM and plateau 
at 10 μM (~25 fold increase) as can been seen in Figure 3B.  Analyzing E-cadherin 
mRNA transcript levels at key time points (3 or 6 hours) or across various concentrations 
may provide additional information when screening newly synthesized libraries.       
Increase in Transcript Levels Observed with Additional Transcription Factors 
 While we were planning to further analyze the RNASeq data in an effort to shed 
some light on the mechanism of action or identify potential candidates as the molecular 
target of these small molecules, we were able to use some accidental revelations to direct 
our analysis towards repressive transcription factors.  The family of nuclear factor of 
activated T cells (NFAT) transcription factors, specifically NFATc1 and NFATc2, are of 
interest to the research conducted in our lab in regards to invasion and metastasis in 
colorectal cancer.     
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 In general, research is uncovering that various isoforms of the NFAT transcription 
factors are functional in tumor cells as well as in the tumor microenvironment, including 
fibroblasts, endothelial cells, and immune cells and understanding the role for each 
isoform will be key.  For example, NFATc1 and NFATc2 have been shown to have 
distinct and opposing roles in tumorigenesis.  NFATc1 is thought to be an oncogene and 
constitutive activity studies in fibroblasts have shown that NFATc1 increases 
proliferation.  NFATc2 is thought to be a tumor suppressor protein and constitutive 
activity studies in fibroblasts have shown that NFATc2 induces cell cycle arrest and 
apoptosis [10, 11].  
 Curiously, RNA samples from SW620 and H520 cells treated with DMSO along 
with a preliminary set of active and inactive analogs were analyzed for effects on 
NFATc1 and NFATc2 mRNA transcript levels while looking at E-cadherin mRNA 
transcript levels (data already collected).  Originally, the data was looked at separately 
and it was noticed that an increase in NFATc1 and NFATc2 transcript levels was 
observed.  Although when we compared all three analyses – E-Cadherin, NFATc1, and 
NFATc2 – we saw a similar trend of increased mRNA transcript levels (Figure 4).  
We further analyzed this finding by collecting RNA from SW620 and H520 
samples treated with DMSO, compound 289, or compound 290 for 24 hours.  The results 
can be seen in Figure 5, in which a similar increase in all three genes is observed with the 
active compound, 289.  In the SW620 cells, we see a much smaller increase in NFATc2 
transcription levels as compared to E-cadherin and NFATc1, which are relatively similar.  
However, in the H520 cells the increase in transcription levels appears relatively constant 
between the three genes analyzed.       
 114 
 
 
 
 
Figure 4.  qPCR analysis comparison of E-cadherin, NFATc1, and NFATc2 after SW620 cells 
were treated with a 10 μM concentration of selected compounds for 24 hours.  All values 
normalized to DMSO control and compound 140 is an inactive analog. 
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Figure 5. qPCR analysis of E-cadherin, NFATc1, NFATc2 mRNA transcript levels after a 10 μM 
treatment of selected analogs for 24 hours in the (A) SW620 and (B) H520 cells. 
 
 
 
Having observed a 24.22-fold increase in E-cadherin mRNA transcript levels after 
6 hours of treatment, we were curious to see the mRNA transcript levels of NFATc1 and 
NFATc2 after 6 hours of treatment.  If the mRNA transcript levels were low then it may 
suggest that the increase in NFATc1 and NFATc2 transcript levels observed at 24 hours 
was a downstream effect resulting from E-cadherin transcription.  However, if the 
transcription levels are elevated after 6 hours of treatment, one could hypothesize that the 
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active analogs are targeting the same mechanism of regulation for all three genes.  Thus, 
NFATc1 and NFATc2 were analyzed in both the SW620 and H520 cells after 6 hours of 
treatment with DMSO, compound 289, or compound 290. 
As seen in Figure 6, RNA was extracted from SW620 or H520 cells treated for 6 
hours with DMSO, compound 289, or compound 290 and used to measure E-cadherin, 
NFATc1, and NFATc2 mRNA transcript levels.   In the SW620 cells all 3 genes have 
increased transcript levels after treatment with compound 289 as compared to DMSO and 
the inactive analog, compound 290.  When comparing transcription levels with the 
SW620 cells from Figure 5a and Figure 6a it appears that E-cadherin levels are 
consistent, NFATc1 levels continue to increase from 6 hours to 24 hours, and NFATc2 
levels are much higher after 6 hours of treatment as compared to 24 hours.  When 
comparing mRNA transcript levels from Figure 5b and Figure 6b it appears that the 
transcription levels remain relatively constant for E-cadherin, NFATc1, and NFATc2 
with only a minor decrease occurring at 24 hours.   However, what is most important 
from Figure 6, is that transcription is increased as well for NFATc1 and NFATc2 
suggested that the changes in gene transcription must be consistent and a result of 
treatment by compound 289.  
We used this knowledge to hypothesize that the small molecules are promoting 
transcription via the same mechanism of action for E-cadherin and the NFAT family of 
transcription factors. Preliminary analysis from a colleague, Bing Zhang, identified two 
E-box binding sites within the promoter regions of NFATc1 and NFATc2.  Similarly, 
there are several known E-box binding sites within the promoter region of the CDH1 
gene (Figure 9).  Thus, further suggesting there must a be constant regulatory 
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transcription factor protein complex that bindings to conserved binding sites within the 
promoter regions of these genes.  
 
 
 
Figure 6. qPCR analysis of E-cadherin, NFATc1, NFATc2 mRNA transcript levels after a 10 μM 
treatment of selected analogs for 6 hours in the (A) SW620 and (B) H520 cells. 
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Active Analogs are Believed to be Promoting Transcription by Altering 
Transcription Factor Binding to E-cadherin Promoter Region 
 We have been working backwards from the original HTS phenotypic response 
assay, restoration of E-cadherin protein expression, in an effort to better understand the 
mechanism of action of these small molecules as well as to move closer towards 
identifying the molecular target.  Thus, observing an increase in E-cadherin mRNA 
transcript levels after treatment with analogs of compound 1, we wanted to look 
specifically at the E-cadherin promoter activity.   A reporter plasmid construct obtained 
from Eric R. Fearon’s laboratory, which consisted of a 1.4 kbp fragment of the E-
cadherin promoter upstream of the firefly Luc gene, was used in preliminary experiments 
to determine if the small molecules acted within this sequence [8].  A representation of 
the E-cadherin promoter fragment located within the reporter plasmid construct (E1) can 
be seen in Figure 7A.    
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Figure 7. (A) E1 E-cadherin promoter reporter plasmid construct (B) Luciferase activity in SW620 
cells transfected with plasmid E1 and treated immediately with a 10 μM concentration of selected 
compounds for 24 hours.  All samples are normalized to DMSO control and compounds 140 and 
290 are inactive analogs. 
 
 
The plasmid was transfected into SW620 and H520 cells and then the cells were 
treated with a 10 μM concentration of selected analogs for 24 hours.  A β-galactosidase 
reporter plasmid was used as a transfection control and was co-transfected with the E-
cadherin promoter reporter plasmid in each well.  The luciferase assay, which was a 
measure of E-cadherin promoter activity, was normalized to the β-galactosidase assay 
results for each sample and then the treatment groups were normalized to the DMSO 
control samples.  The results for the SW620 and H520 cells can be seen in Figure 7B and 
Figure 8 respectively. 
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Figure 8. Luciferase activity in H520 cells transfected with plasmid E1 and treated immediately 
with a 10 μM concentration of selected compounds for 24 hours.  All samples are normalized to 
DMSO control and compound 140 is an inactive analog. 
 
 
 
Much to our surprise, as this was merely a fragment of the E-cadherin promoter 
and there are known upstream and downstream regulatory elements, we observed 
significant (p value < .005) increases in luciferase activity between the active selected 
analogs and the DMSO.  Additionally, we saw no luciferase activity in the inactive 
analogs, compounds 140 and 290, further confirming that the induction observed was a 
result of the mechanism of action of the active analogs.   
With this information, we then directed our attention to narrowing down the 
region in which the active analogs were interacting and thus promoting transcription.  In 
order to do this, we obtained 7 E-cadherin promoter reporter plasmid constructs from Ju 
Hshiung Chen’s laboratory.  Representation of these 7 E-cadherin promoter plasmid 
constructs (E2-E8) can be seen in Figure 9, and varied from 1.2 kbp of the E-cadherin 
promoter to 200 bp of the E-cadherin promoter upstream of the start codon [9].  Similar 
to plasmid E1, the E-cadherin promoter fragments in plasmids E2-E8 were directly 
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upstream from the firefly Luc gene; thus luciferase activity was utilized as a readout for 
E-cadherin promoter induction after treatment with selected analogs.  
 
 
 
Figure 9. (A) E-Cadherin promoter sequence and highlighted transcription factor binding sites 
within the promoter sequence (B) E-cadherin promoter plasmid constructs that were synthesized 
(Liu, et al 2005). 
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 I began by transfecting the SW620 cells with the smallest E-cadherin promoter 
plasmid (Plasmid E8) and then transfecting sequentially from smallest to largest E-
cadherin promoter plasmid (E8  E2).  Based on the data published from Chen’s 
laboratory using the plasmids, I thought that there would be no activity in at least the 
smallest plasmid, E8,  as seen in the MCF7 positive cell line [9].  As can be seen in 
Figure 10, there was a 14.5-fold induction in luciferase activity after the treatment with 
the active analog, compound 289, following transient transfection of plasmid E8 in the 
SW620 cells.   This induction in luciferase activity remained elevated with transfection of 
all the plasmids, E2-E8, followed by treatment with the compound 289 for 24 hours.  
However, there was a noticeable increase from 10-15-fold induction of luciferase activity 
in Plasmids E8 and E7 and the 26.9-fold induction in luciferase activity from Plasmid E6.   
There was a dip in induction of luciferase activity with the transfection of Plasmid E4, 
16.9-fold, but it returned with the transfection of Plasmid E3.  While luciferase induction 
remains elevated throughout each plasmid transfection, the fluctuation may be due to 
additional activating and repressing binding sites being available on the E-cadherin 
promoter region within the plasmid.  However, the important note is the significant 
induction in the smallest plasmid, E8.  
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Figure 10. Luciferase activity in SW620 cells transfected with plasmid E8 – E2 and treated 
immediately with a 10 μM concentration of selected compounds for 24 hours.  All samples are 
normalized to DMSO control and compound 290 an inactive analog. 
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It is known that there are 2 Snail transcription factor binding sites, or E-box sites, 
within the first 200 base pairs of the E-cadherin promoter.  Additionally, one of these 
Snail transcription factor binding sites is located after the start codon [9].  Thus, the 
active compounds may be relieving the repression of Snail and ultimately the entire Snail 
repression binding complex, which includes HDAC 1/2.  Further research will need to be 
conducted in order to determine if the Snail – HDAC 1/2 complex is being disrupted by 
our active compounds. 
 
Discussion 
 
 Here we report the preliminary understanding of the mechanism of action for 
identified small molecules that restore E-cadherin expression.  Due to steep SAR 
surrounding the original screening hit, compound 1, and results from our preliminary 
screens we opted to take a biological approach to uncover the mechanism of action.  We 
began by confirming that E-cadherin mRNA levels were upregulated upon treatment with 
compound 1 and active analogs.  In addition, we looked specifically at when transcription 
was being “turned on” by the active compounds by conducting a time course experiment 
over 16 hours.  Since all of our protein expression assays had been conducted after a 24 
hour treatment, we were surprised to see that transcription of the CDH1 gene was being 
“turned-on” after 3 hours, with a 7.26-fold increase in E-cadherin mRNA transcript levels 
with treatment of compound 289.  Additionally, it appears that transcription levels 
plateau at a 10 μM treatment with a slight induction occurring at 500 nM. 
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 However, our thoughts of pursuing transcriptional regulation were further 
supported when we observed that NFATc1 and NFATc2 transcription levels increased in 
parallel with E-cadherin expression after both 6 hour and 24 hour treatments with 
compounds.  This was observed in both the SW620 and H520 cells.  At this point it 
appeared the next step would be to take advantage of a 1.4 kbps E-cadherin promoter 
reporter plasmid that was present in the lab.  As this is only a section of the E-cadherin 
promoter, which is known to be 2.5 kbps, and with known enhancer elements up and 
downstream of the promoter region, we were unsure if the compounds would elicit an 
induction in luciferase activity after transfection of plasmid E1 into the SW620 and H520 
cells.  However, we were excited to observe a 5-fold induction of luciferase activity with 
treatment of compound 1 and preliminarily profiled active analogs.  Additionally, a 
roughly 10-fold induction was seen with compound 289 in the SW620 cells, suggesting 
that the compounds are acting somewhere along the 1.4 kbp portion of the E-cadherin 
promoter to alleviate transcription repression or promote transcription activation.  
Through literature searches to identify the regulatory element binding sites within this 
fragment of the E-cadherin promoter we found Chen’s laboratory’s published research, 
which included the synthesis of 7 truncated E-cadherin promoter reporter plasmids.  
Compounds 289 and 290 were used to screen the 7 plasmids (Plasmids E2 –E8) in order 
to identify a narrow region of the E-cadherin promoter affected by the treatment of active 
compounds to relieve repression of CDH1 transcription.  To our surprise, a 14-fold 
induction of luciferase activity was observed in the smallest plasmid, E8, which includes 
only a 38 bp promoter fragment prior to the start codon.  There are two known Snail 
binding sites within this region of the E-cadherin promoter.  One is within the 38 bp prior 
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to the start codon, and one is found within the 135 bp following the start codon but before 
the first exon (or in the plasmid the luciferase gene).  In addition, the induction of 
luciferase activity remained elevated (25-30 fold induction in some plasmids) within all 
of the plasmids suggesting that this small fragment contains the region of the promoter 
effected by our molecules.  
 Having narrowed the search to a small portion of the E-cadherin promoter we will 
be able to focus our attention on the transcription factor binding sites within this ~200 bp 
region of the promoter in an effort to identify the molecular target and further elucidate 
the mechanism of action.  Additionally, as seen in Figure 9, it is shown that there are two 
Snail binding sites.  Due to the similarity between our compounds and HDAC inhibitors 
as well as HDAC1/2 forming a known complex with Snail, this seems like a logical place 
to begin our efforts to determine if the molecules disrupt complex formation.  
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CHAPTER V 
  
ADDITIONAL BIOLOGICAL ANALYSIS OF NATURAL PRODUCTS 
AND UNNATURAL ANALOGS 
 
Introduction 
 
 In addition to my thesis research, I also conducted experiments to biologically 
evaluate synthesized natural compounds and their unnatural analogs.  There were two 
main projects that I provided biological data for:  the total synthesis of Tambjamine K 
and unnatural analogs synthesized by Leslie N. Aldrich and the total synthesis of (+)-7-
Bromotrypargine and unnatural analogs synthesized by John T. Brogan.  Both projects 
will be discussed in brief within this chapter. 
 The tambjamines A-J are a 2,2’-bipyrrolic class of cytotoxic alkaloids with 
diverse aliphatic termini isolated from bacteria and marine invertebrates.  Members of 
this class have demonstrated a wide range of biological activities, including antitumor, 
antimicrobial, and immunosuppressive properties [1-8].  Gavagnin and co-workers 
described the isolation and characterization of a new member of the tambjamine family, 
tambjamine K, from the Azorean nudibranch Tambja ceutae, which displayed                                                         
 Parts of Chapter 5 referenced from two publications: Leslie N. Aldrich, Sydney L. Stoops, Brenda S. 
Crews, Lawrence J. Marnett, Craig W. Lindsley. ‘Total Synthesis and Biological Evaluation of 
Tambjamine K and a Library of Unnatural Analogs’. Bioorganic & Medicinal Chemistry Letters. 
September 1 2010, 20(17): 5207-5211 
John T. Brogan, Sydney L. Stoops, Brenda C. Crews, Lawrence J. Marnett, Craig W. Lindsley. ‘Total 
Synthesis (+)-7-Bromotrypargine and Unnatural Analogues: Biological Evaluation Uncovers Activity at 
CNS Targets of Therapeutic Relevance’. ACS Chemical Neuroscience. November 16 2011, 2(11) 633-639  
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antiproliferative and cytotoxic effects against tumor cell lines [9]. Based on these data, 
we initiated an effort for the total synthesis and biological evaluation of tambjamine K, 
along with a library of unnatural analogs with unprecedented diversity in the eastern C7 
position (Figure 1). 
 
 
 
Figure 1.  Total synthesis of tambjamine K and unnatural analogs 
 
 
 β-Carboline alkaloids are a prevalent class of biologically active natural products 
from marine organisms.  They exhibit diverse structural features and distinct 
neuropharmacological profiles [10, 11].  Our lab has worked extensively in this arena and 
we were recently attracted to a class of β-carboline alkaloids represented by the 
trypargines 4-6 (Figure 2), as these alkaloids mapped well onto the H3 pharmacophore 
model and offered a synthetic challenge [12-15].   The H3 receptor (H3R) is a presynaptic 
autoreceptor within the Class A GPCR family, but also functions as a heteroreceptor 
modulating levels of neurotransmitters such as dopamine, acetylcholine, norepinephrine, 
serotonin, GABA, and glutamate.   Thus, H3R has garnered a great deal of interest from 
the pharmaceutical industry for the possible treatment of obesity, epilepsy, sleep/wake 
disorders, schizophrenia, Alzheimer’s disease, neuropathic pain, and ADHD [16-18].  
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Both trypargine and 6-hydroxytrypargine are highly toxic alkaloids. (+)-7-
Bromotrypargine, was only recently isolated by Quinn from the Australian marine sponge 
Ancornia sp., and found to possess antimalarial activity.   6-Bromotyramine was isolated 
along with (+)-7-Bromotrypargine in similar quantities, and is believed to be a key 
biosynthetic precursor [19].  Based on the neuropharmacological profiles of β-carboline 
alkaloids, and the electron-deficient nature of (+)-7-Bromotrypargine, relative to the 
electron-rich congeners trypargine and 6-hydroxytrypargine, which might diminish the 
cytotoxicity, the total synthesis of  (+)-7-Bromotrypargine and biological evaluation 
seemed warranted. 
 
 
 
Figure 2. Structures of the (+)-trypargines 4-6 and 6-bromotyramine 7. 
 
 
 
 
 
 
Methods and Materials 
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Cell Culture  
  A colorectal adenocarcinoma cell line, SW620, and a squamous cell lung 
carcinoma cell line, H520, were obtained from the American Type Culture Collection 
(Manassas, VA) and maintained in a humidified atmosphere of 5% CO2 in air at 37 °C.  
The cells were routinely cultured in RPMI 1640 supplemented medium with 10% fetal 
bovine serum (Atlanta Biologicals, GA) and 100 μg/mL penicillin-streptomycin.   
Viability Assay 
 SW620 and H520 cells (2.5 x 104/100 μL) were seeded in 96-well microtiter 
plates prior to treatment. Cells were treated with a 10 μM concentration of synthesized 
compound in quadruplicate for 24 hours and 48 hours in RPMI 1640 supplemented 
medium and 100 μg/mL penicillin-streptomycin.  The Quick Cell Proliferation Assay Kit 
from BioVision (Mountain View, CA) was used to measure viability. The complete 
protocol can be referred to in the Methods & Materials section of Chapter 3. 
Invasion Analysis 
SW620 cells (1.0 x 106/mL) were seeded in 6 cm round dishes prior to treatment. 
Cells were treated with a 10 μM concentration of synthesized compound for 24 hours in 
RPMI 1640 supplemented medium and 100 μg/mL penicillin–streptomycin. 40 μL (2.5 
mg/mL) of BD Matrigel Basement Membrane Matrix (BD Biosciences, Bedford, MA) 
was added to the top of the insert of a 24-well Transwell Permeable Support plates with 
polycarbonate membrane with 8 μm pore size (Corning Inc, Corning, NY). Then the cells 
were trypsinized and 3 x 105/250 μL cells were added to the top of the chamber in serum 
free RPMI medium, and 1 mL of RPMI medium with 10% FBS was added to the bottom 
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of the well. Then the plates were incubated for 72 hours at 37 °C in a humidified 
incubator with 5% CO2 in the air. Then the wells were stained with 1% crystal violet in 
50% methanol for 1 hour and washed in PBS. The membrane was cut off, adhered to a 
slide with glycerol, and analyzed in 20x� field via microscopy. 3 – 20x� fields were 
quantified per membrane. 
Proliferation Analysis 
SW620 and H520 cells (2.5 x 104/100 μL) were seeded in 96-well microtiter 
plates prior to treatment. Cells were treated with a 10 μM concentration of selected 
compounds in triplicate for 48 hours in RPMI 1640 supplemented medium and 100 
μg/mL penicillin-streptomycin.  The CycLex® Cellular BrdU ELISA Kit from MBL 
International (Woburn, MA) was used to measure proliferation.  The complete protocol 
can be referred to in the Methods & Materials section of Chapter 3.   
 
Results 
 
Biological Evaluation of Tambjamine K and Synthesized Unnatural Analogs 
 As mentioned, the total synthesis of tambjamine K was reported along with the 
synthesis of a library of unnatural analogs. The analogs were designed to incorporate 
functionalized benzyl, heteroaryl moieties, and other previously undescribed analogs with 
varying degrees of lipophilicity and basicity to further develop SAR (Figure 3).  
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Figure 3. Library of unnatural analogs synthesized to characterize SAR further surrounding this 
2,2’-bipyrrolic class of cytotoxic alkyloids. Reagents and conditions: RNH2, 0.87 M HCl, MeOH, 
room temperature to 50 °C, 24–48 hours, 35–88%. 
 
 
  
 
 
 Based on viability data collected in the HTC116 and MB231 cell assays, we then 
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evaluated select unnatural analogs in a standard 48 hour cell viability assay (Figure 4) 
using another colorectal line (SW620) and a lung cancer cell line (H520).  Interestingly, 
9, the most potent tambjamine analog in both the HCT116 (IC50 = 146 nM) and MB231 
(IC50 = 362 nM) viability assays, had no effect on viability in either the SW620 or the 
H520 cell lines. However, unnatural analog 3b, displayed a significant effect on 
inhibiting viability in both cancer cell lines, while other analogs showed varying effects.   
Further analysis would need to be conducted to determine if the decrease in viability was 
a result of apoptosis (or cell death) or inhibition of proliferation.   
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Figure 4. Single point (10 μM) screen of select unnatural tambjamine analogs in a 48 hour cell 
proliferation assays. (A) Proliferation assay with SW620 cell line; (B) proliferation assay with 
H520 cell line. 
 
 
 
 Although we were more interested in the compounds abilities to block invasion.  As 
both unnatural tambjamine analogs 9 and 3e displayed minimal to no effect on viability 
in SW620 cells, we examined their ability to block invasion in this cancer cell line, as the 
ability of tumor cells to invade into the surrounding microenvironment is a defining step 
in tumor progression.   As shown in Figure 5, both 9 and 3e significantly blocked 
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invasion, with compound 9 completely inhibiting invasion.  The data suggests that while 
the compounds do not effect SW620 cell viability they do significantly block invasion. 
 
 
 
Figure 5. Single point (10 μM) screen of select unnatural tambjamine analogs in 72 hour cell 
invasion assay in the SW620 cell line. 
 
 
 
Biological Evaluation of (+)-Bromotrypargine and Synthesized Unnatural Analogs 
As 4 and 5 are highly toxic alkaloids, we first evaluated 6 in a standard 
cytotoxicity assay and found 6 to be non-toxic up to 20 μM, suggesting the 
pharmacological profile might diverge from 4 and 5.  This surprising result led us to 
study 6 in our standard HCT116 colon carcinoma cell viability assay [20, 21].  Here as 
well, 6 had no affect on HCT116 cell viability after 48 hours.  In contrast, advanced 
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intermediate 8 (Figure 6), an unnatural analog of 7, displayed an IC50 of 3 μM in this 
assay, completely killing the cells after 48 hours.   
 
 
 
Figure 6. The final step towards the synthesis of (+)-7-bromotrypargine which displays the unnatural 
precursor analog (8) screened in the proliferation and viability assays. 
 
 
These data prompted examination of unnatural analog 8 in an additional 
colorectal cancer (SW620) and lung cancer (H520) cell lines [22]. Interestingly, 8 had 
dramatic effect inhibiting cell viability in the WST-1 assay at various concentrations.  
This lead us to further elucidate a possibly mechanism for the decrease in viability.  For 
this we screened compound 6 and 8 in the BrdU assay to look at the compounds’ effects 
on proliferation.  Again, we saw that compound 8 significantly reduced proliferation of 
both the SW620 and H520 cells at various concentrations (Figure 7).  Overall, compound 
8 (10 μM) had similar effects on viability and proliferation as the positive control, 
Sodium Butyrate.  Collectively, these data informed us of two important points: 1) the 
pharmacology of the more electron deficient (+)-7-bromotrypargine (6) is distinct from 4 
and 5 and warrants further biological evaluation as it lacks toxicity, and 2) unnatural 
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analog 8 possesses an intriguing pharmacological profile warranting the synthesis and 
characterization of additional unnatural analogs of 6.  
 
 
 
Figure 7. Multiple treatment points for (+)-7-bromotrypargine and the unnatural intermediate analog in cell 
proliferation and viability assays in both the SW620 and H520 cell lines.  Sodium butyrate was used as a 
positive control. (A) WST-1 viability assay (B) BrdU proliferation assay. 
 
 
Discussion 
 
 In summary, we completed the first total synthesis of tambjamine K in 18% 
overall yield coupled with biological evaluation in viability assays in both colon 
(HCT116) and breast cancer (MB231) cell lines. We also prepared a library of unnatural 
tambjamine analogs with unprecedented diversity and improved biological activity 
 139 
against a number of tumor cell lines in viability and invasion assays. This effort 
demonstrated that subtle changes to the tambjamine core afford varying degrees of 
selectivity against different tumor cell lines. These data argue for further exploration of 
the tambjamine scaffold coupled with evaluation (viability, proliferation, and invasion) in 
additional human tumor cell lines. Current efforts are focused on synthesizing a second 
generation library including the discrete enantiomers of 3b and 3e, chiral a-methyl 
congers of the benzylic analogs 3m–3w, and more focused analogs based on 9. In 
parallel, we are working to identify the molecular target(s) for these unnatural analogs by 
evaluating 9, 3b, and 3e against large screening panels of kinases, growth factor 
receptors, and phosphatases as a primary approach.  
In summary, we have completed the first total synthesis of (+)-7-bromotrypargine 
(6) in nine steps (8 steps longest linear sequence) in 36.9% overall yield from commercial 
materials.  Biological evaluation of 6 and an advanced intermediate 8 proved very 
exciting, with 6 displaying divergent pharmacology from related β-carbolines 4 and 5, 
while 8 was extremely cytotoxic in mutiple non-transformed and colon cancer cell lines.  
Importantly, receptor-profiling efforts identified 6 as a moderately potent, dual 
NET/DAT inhibitor, and only the second known compound, and chemotype, to display 
such a pharmalogical profile devoid of SERT activity.  This finding was in addition to the 
anticipated activity as an H3 antagonist, based on the H3 pharmacophore model.  The 
intriguing pharmacological profile led us to then explore chemistry to access unnatural 
analogs.  These reactions will serve as the groundwork for a larger effort aimed at 
unnatural analog synthesis to develop SAR around 6 and to optimize dual NET/DAT 
activity.  
 140 
References 
 
1. Wrede, F. and O. Hettche, Über das Prodigiosin, den roten Farbstoff des Bacillus 
Prodigiosus (I. Mitteil.). Ber. Dtsch. Chem. Ges. B., 1929. 62(9): p. 2678-2685. 
 
2. Wasserman, H.H., D.J. Friedland, and D.A. Morrison, A novel 
dipyrrolyldipyrromethene prodigiosin analog from Serratia marcescens. 
Tetrahedron Lett, 1968. 6: p. 641-4. 
 
3. Pinkerton, D.M., M.G. Banwell, and A.C. Willis, Total syntheses of tambjamines 
C, E, F, G, H, I and J, BE-18591, and a related alkaloid from the marine 
bacterium Pseudoalteromonas tunicata. Org Lett, 2007. 9(24): p. 5127-30. 
 
4. Lindquist, N. and W. Fenical, New tamjamine class alkaloids from the marine 
ascidian Atapozoa sp. and its nudibranch predators. Origin of the tambjamines in 
Atapozoa. Experientia, 1991. 47(5): p. 504-506. 
 
5. Kazlauskas, R., et al., A blue pigment from a compound ascidian. Australian 
Journal of Chemistry, 1982. 35(1): p. 215-217. 
 
6. Carte, B. and D.J. Faulkner, Role of secondary metabolites in feeding associations 
between a predatory nudibranch, two grazing nudibranchs, and a bryozoan 
Journal of Chemical Ecology, 1986. 12(3): p. 795-804. 
 
7. Carte, B. and D.J. Faulkner, Defensive metabolites from three nembrothid 
nudibranchs. J. Org. Chem, 1983. 48(14): p. 2314-2318. 
 
8. Blackman, A.J. and C. Li, New Tambjamine Alkaloids From the Marine Bryozoan 
Bugula dentata. Australian Journal of Chemistry, 1997. 47(8): p. 1625-1629. 
 
9. Carbone, M., et al., A new cytotoxic tambjamine alkaloid from the Azorean 
nudibranch Tambja ceutae. Bioorg Med Chem Lett. 20(8): p. 2668-70. 
 
10. Phuong, N.M., et al., Two new beta-carboline alkaloids from Hedyotis capitellata 
var. mollis. Planta Med, 1999. 65(8): p. 761-2. 
 
11. Cain, M., et al., Beta-carbolines: synthesis and neurochemical and 
pharmacological actions on brain benzodiazepine receptors. J Med Chem, 1982. 
25(9): p. 1081-91. 
 
12. Lindsley, C.W., et al., A 'one pot' microwave-mediated synthesis of the basic 
canthine skeleton: expedient acces to unnatural beta-carboline alkaloids. 
Tetrahedron Lett, 2003. 44: p. 4495-4498. 
 
 141 
13. Kennedy, J.P., M.L. Breininger, and C.W. Lindsley, Total synthesis of 
Eudistomins Y1-Y6. Tetrahedron Lett, 2009. 50: p. 7076-7069. 
 
14. Cesar, L.M., et al., Isolation and chemical characterization of PwTx-II: a novel 
alkaloid toxin from the venom of the spider Parawixia bistriata (Araneidae, 
Araneae). Toxicon, 2005. 46(7): p. 786-96. 
 
15. Akizawa, T., et al., Trypargine, a new tetrahydro-beta-carboline of animal origin: 
isolation and chemical characterization from the skin of the African rhacophorid 
frog, Kassina senegalensis. Biomed Res, 1982. 3: p. 232-234. 
 
16. Lebois, E.P., C.K. Jones, and C.W. Lindsley, The evolution of histamine H 
antagonists/inverse agonists. Curr Top Med Chem. 11(6): p. 648-60. 
 
17. Leurs, R., et al., The histamine H3 receptor: from gene cloning to H3 receptor 
drugs. Nat Rev Drug Discov, 2005. 4(2): p. 107-20. 
 
18. Hudkins, R.L. and R. Raddatz, Recent advances in drug discovery of histamine 
H3 antagonist. Annu Rep Med Chem, 2008. 42: p. 49-63. 
 
19. Davis, R.A., et al., (+)--7-Bromotrypargine: an antimalarial beta-carboline from 
the Australian marine sponge Ancorina sp. . Tetrahedron Lett, 2010. 51: p. 583-
585. 
 
20. Aldrich, L.N., et al., Total synthesis and biological evaluation of tambjamine K 
and a library of unnatural analogs. Bioorg Med Chem Lett. 20(17): p. 5207-11. 
 
21. Daniels, R.N., et al., Progress toward the total synthesis of lucentamycin A: total 
synthesis and biological evaluation of 8-epi-lucentamycin A. J Org Chem, 2009. 
74(22): p. 8852-5. 
 
22. Stoops, S.L., et al., Identification and optimization of small molecules that restore 
E-cadherin expression and reduce invasion in colorectal carcinoma cells. ACS 
Chem Biol. 6(5): p. 452-65. 
 
 
 142 
CHAPTER VI 
 
CONCLUDING REMARKS 
 
Summary 
 
In summary, a novel high-throughput screen was developed to identify small 
molecules that restored E-cadherin expression in the SW620 cell line followed by 
medicinal chemistry employing iterative analog library synthesis to develop SAR.  
Preliminary optimization of the screening hit has shown it is possible to synthesize small 
molecules that have an improved ability to restore E-cadherin expression compared to the 
initial screening hits. This restoration of protein has been confirmed by visualization of 
E-cadherin at the membrane via immunofluorescent microscopy.  Further biological 
evaluation of profiled analogs has shown a minimal effect on cell proliferation, decrease 
in cellular invasion, and no cytoxicity in a normal-like epithelial cell line (MCF10A). 
In addition we began to focus our attention on understanding the mechanism of 
action of these small molecules to restore E-cadherin expression. Quantitative PCR 
analysis has shown that treatment with selected small molecules increased mRNA 
expression 24.22-fold after 6 hours, which increased further to 58.68-fold after 16 hours 
of treatment, suggesting the small molecules are altering transcription of the CDH1 gene.  
This was supported by experiments conducted using a plasmid construct containing a 1.4 
kbp fragment of the E-cadherin promoter and luciferase reporter.  After transfection, the 
cells were treated with selected compounds, lysed, and luciferase activity was measured.  
 143 
It was shown that selected active analogs had a significant increase in luciferase activity 
as compared to DMSO or an inactive analog, which were used as controls.   
More specifically, this suggests that the small molecules are specifically effecting 
transcription within the 1.4 kbp promoter region of the CDH1 gene.  Use of 7 truncated 
E-cadherin promoter reporter plasmids in the same experiment identified the smallest 
plasmid (E8) consisting of ~200 base pairs as the target for these compounds.  Future 
work will include further pursuing this narrowed region of the E-cadherin promoter in an 
effort to identify the mechanism of action and molecular target for these small molecules.  
 
 
On-Going Efforts 
 
 On-going efforts within the project are two-fold: analyzing and vetting the RNA-
Seq data and EMT studies.  The main focus is extracting data from the RNA-Seq analysis 
that was conducted and used to confirm that E-cadherin was upregulated on a 
transcriptional level.  Knowing that NFATc1 and NFATc2 appear to be under the same 
repressed transcriptional regulation that is being relieved by treatment with the 
compounds aids in narrowing down potential transcription factors or associated proteins 
in complex that are being targeted by the compounds.  The number of possible targets can 
be further narrowed down since we have identified a 200 bp region of the E-cadherin 
promoter in which we believe the compounds are acting.  Additionally, with the synthesis 
of more efficacious and potent compounds, we will send new RNA samples from DMSO, 
compound 290, and compound 289 treated SW620 cells for RNA-Seq analysis.  Our 
rational is that since we see a 7.26-fold increase in E-cadherin mRNA levels with 
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compound 289 at 3 hours; we may find more distinct changes in mRNA levels genome 
wide.  Additionally, this may aid in identifying a key binding site region that is conversed 
within the promoter region of all upregulated genes identified in the RNA-Seq analysis.  
Such information would allow for a more narrowed targeted approach towards 
identifying the molecular target. 
 The second on-going effort includes studying compound 289 in two distinct EMT 
cell models: the LIM1863 and NMuMg cells.  Both cell lines can be induced to undergo 
EMT through the addition of TNF-α and/or TGF-β.  The LIM1863 cell line is a unique 
colon carcinoma cell line that consists of organoids, which are morphologically and 
functionally organized and maintain tight junctional complexes and epithelial polarity in 
suspension culture [1, 2]. The LIM1863 organoids will undergo an EMT conversion from 
this well-differentiated organoid structure to a migratory monolayer phenotype (adhering 
to the plate bottom) in response to TGF-β [3, 4]. Moreover, it has been found that the 
EMT process was accelerated dramatically by co-stimulation with the inflammatory 
cytokine TNF-α [5].  Thus, we plan to take advantage of this unique and inducible EMT 
model to determine if our active analogs are capable of reverting and/or blocking EMT.  
The data will be collected using immunofluorescent microscopy and qPCR to identify 
changes in expression of hallmark EMT markers.  In addition the distinct morphological 
change of the LIM1863 cells from organoids to a monolayer will provide initial 
confirmation to the effectiveness of compound 289.  Identical experiments will be 
conducted in the NMuMg cell line, which is an immortalized mouse mammary gland 
epithelial cell line.  Similarly, the NMuMg cell line has been well established as a cell 
line that can undergo EMT via growth factor stimulation, specifically TGF-β [6, 7].  
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Overall, we hope to show that our active compounds are capable of reverting or blocking 
EMT, thus providing proof of concept for the molecules.  At a minimum this would allow 
for the molecules to be used as research tools to further understand EMT during tumor 
progression. 
 
Future Directions 
 
 There are two immediate directions of the project that will be addressed in the 
upcoming months.  The first, and most important, is to identify the molecular target of 
compound 1 and synthesized analogs.  We believe the mechanism of action of these 
small molecules is to release the repression of the CDH1 gene thus allowing for 
transcription of the gene and ultimately restoration of the E-cadherin protein at the 
membrane.  However, there are several repressor complexes as well as multiple binding 
sites for several repressor transcription factors (e.g. Snail, Snail, Twist, Zeb1).  Many of 
these complexes also coordinate the methylation of DNA and deacetylation of histones 
within a gene promoter regions.  Once the molecular target is identified, we will be able 
to better understand the specific mechanism of action and series of events within the cell 
that lead to E-cadherin restoration.   
 Determining the molecular target will occur through a dual approach:  biological 
and chemical.  As seen in Chapter 4, there were 7 plasmids with varying lengths of the E-
cadherin promoter region from 200 base pairs to 1.2 kbp, which upon transfection into 
the SW620 cells and treatment with DMSO or selected analogs showed that the 
compounds were inducing transcription observed as an induction of luciferase activity. It 
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is believed the active compounds are releasing repression by interacting with proteins 
bound to the first 200 base pairs of the E-cadherin promoter (plasmid E8).  Within the 
first 200 base pairs of the promoter region there are several binding sites for the Snail 
protein; E-box binding sites.  Several approaches can be taken to confirm that the small 
molecules are disrupting the Snail repressor complex.  A gel shift experiment, EMSA,  
using oligos containing the same E-cadherin promoter sequence that is in Plasmid 8 could 
confirm if Snail is bound after treatment with the selected active analogs or if there is 
disruption in complex formation on the promoter.  Such an experiment can be supported 
through Co-IP experiments directed at Snail or key repressor complex proteins. 
 Once the repressor complex has been identified, additional biological research can 
be conducted in an effort to tease out if the compounds are preventing complex binding 
directing to the DNA binding site (ChIP), complex formation (Co-IP), or direct inhibition 
(Co-IP) of one or more specific proteins in the complex.  As mentioned the second 
approach that will be utilized is a chemical approach via affinity chromatography.  The 
most recent series of analogs synthesized opened up the middle carbon linker providing 
additional points where photoaffinity labels may be tolerated; retaining E-cadherin 
restoration activity.  If such molecules are synthesized, an affinity chromatography 
protocol can be utilized to try and pull out the molecular target.   
 Identifying the molecular target will be key in both understanding the mechanism 
of action as well as further developing SAR around compound 1.  Knowing the molecular 
target may identify additional pathways that may be targeted in a multi-therapy approach 
to prevent invasion or induce apoptosis, which will be discussed further below.  In 
addition, it will allow for in vitro direct biochemical assays or in vivo cellular assays to be 
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developed for measuring the function of the identified target.  This will allow for SAR to 
be established specifically around the molecular target as opposed to measuring a desired 
phenotypic response.  SAR directed at the molecular target will allow for the increase in 
potency and efficacy of the small molecules for the molecular target as well as allow us 
to build small molecule libraries outside the current patent landscape.   
 The second area of future research will be to identify potential synergistic effects 
between the most effective compound 1 analogs and the standard of care 
chemotherapeutics used for the treatment of colorectal cancer.  The first 
chemotherapeutic that will be analyzed in combination with our small molecules will be 
5-Fluorouracil (5-FU).  5-FU is a pyrimidine analog and acts as an irreversible 
thymidylate synthase inhibitor preventing the synthesis of thymidine, a necessary 
nucleotide required for DNA replication, thus resulting in cell death. In colorectal cancer, 
5-FU based chemotherapy treatment regimens improve overall and disease-free survival 
of patients with resected stage III colorectal cancer.  However, developed tumor cell 
resistance to 5-FU is a major limitation and response rate for advanced stage colorectal 
cancer is only 10-15% [8-10].  Combinations with new chemotherapies such as 
oxaliplatin have improved the response rate to 40-50%, but there is still a need to better 
improve the current therapeutic strategies especially for late stage disease [11].  
 Therefore, viability and proliferation will be measured in the SW620 cells after 
the treatment with a subtherapeutic dose of 5-FU in combination with the best compound 
1 analogs.  Variables to consider during these experiments will include specific doses of 
5-FU as well as selected analogs, length of incubation, and treatment time (e.g. whether 
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co-dosed or a staggered treatment).  Additionally, if synergy between 5-FU and the active 
analogs is evident, induction of apoptosis will also be analyzed.   
 Upon identification of the molecular target, signaling pathways may be identified 
that are affected by the signaling cascade triggered in response to our compounds.  This 
may allow for pathway specific inhibitors to be tested in combination with our 
compounds to elicit a synergistic and tumor specific effect.   Additionally, it may be 
found that through the molecular target and mechanism of action that tumor cells may 
become ‘re-sensitized’ to common chemotherapeutics that lead to resistance.  An 
example of such is restoration of EGFR protein with treatment of an HDAC inhibitor in 
lung cancer, thus restoring tumor sensitivity to EGFR inhibitors [12].  Since our 
compounds elicit a transcriptional effect, similar to HDAC inhibitors, this may be another 
avenue to pursue in specific lung cancer cell lines, such as the H520 cells.  
 Identifying the molecular target as well as potential synergistic effects with 
chemotherapeutics currently in the clinic will identify the therapeutic relevance of these 
molecules.  If therapeutic relevance is identified there are several necessary avenues of 
research that will need to be pursued to push the project forward in a drug discovery 
manner.  First, iterative parallel libraries of small molecules surrounding compound 1 as 
well as active analogs, such as compound 289, will need to be synthesized to further 
optimize the SAR as well as to identify proprietary compounds.  Selected optimized 
compounds will need to undergo traditional in vitro and in vivo DMPK studies to 
understand the metabolism of the small molecules.  Concurrently, preliminary cancer 
studies in mouse models suited to replicate the specific cancer type should be conducted 
to determine tumor response to compound treatment in order to provide preclinical data.   
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 I can only hope that the small molecules synthesized in my research aid in the 
advancement of cancer therapeutic development either as a targeted therapy or as a 
research tool to further understand the signaling pathways involved in EMT and invasion.   
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Table 1. 
 
Compound R WB
a 
SW620 
WBa 
H520 
ICWb 
SW620 
ICWb 
H520 
 
1 
 
 
5.68 5.55 2.19 4.79 
 
5 
 
 
7.30 10.06 5.03  
 
6 
  
6.98 9.68 4.71  
 
7 
  
5.05 10.01   
 
8 
  
0.97 1.20   
 
9 
  
4.29 8.05 3.88  
 
10 
  
5.34 8.01 4.43  
 
11 
  
0.96    
 
12 
 
 
0.84    
 
13 
 
 
0.92    
 153 
 
14 
 
 
0.90    
 
15 
 
 
0.75    
 
16 
 
 
0.80    
 
17 
  
4.97  5.41  
 
18 
  
0.86    
 
19 
 
 
1.36 3.24   
 
20 
 
 
1.13    
 
21 
  
8.11 10.84 4.15  
 
22 
 
 
1.19    
 
23 
 
 
1.12    
 
24 
  
3.51 6.10 2.71  
 
25 
 
 
1.06    
 
26 
  
1.25    
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27 
 
 
1.18    
 
28 
 
 
1.13    
 
29 
  
2.29 1.97 1.17 1.10 
 
30 
  
2.71 2.89 4.21  
 
31 
  
12.90 4.55 4.49  
 
32 
  
13.25 4.62 3.50  
 
33 
  
2.50  0.72 1.65 
 
34 
 
 
 
8.91 
 
9.20 
 
4.44 
 
 
 
 
35 
 
 
 
1.63 
  
0.91 
 
0.83 
 
36 
 
 
 
8.44 
 
5.38 
 
3.96 
 
4.59 
 
37 
 
 
   
1.19 
 
2.12 
 
38 
 
 
   
1.17 
 
0.56 
 
39 
  
   
3.81 
 
3.84 
 
40 
  
  3.10 4.16 
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41 
  
  2.58 2.28 
 
42 
  
  0.14 1.76 
a Data is fold change in E-cadherin restoration above a DMSO control as measured by Western blot for compound 
treatment at 10 µM. (TSA = 3.74). 
b Data is fold change in E-cadherin restoration above a DMSO control as measured by In-Cell Western assay for 
compound treatment at 10 µM. (TSA = 2.37). 
 
 
 
Table 2. 
 
Compound R WB
a 
SW620 
WBa 
H520 
ICWb 
SW620 
ICWb 
H520 
 
43 
  
2.43 3.74 1.58  
 
44 
  
3.55 6.93 3.90  
 
45 
  
4.40 8.87 6.46  
 
46 
  
2.72 8.36 3.92  
 
47 
 
 
1.13  1.25  
 
48 
 
 
1.20    
 
49 
  
1.18  1.61  
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50 
 
 
4.11 2.41 4.54  
 
51 
  
3.17 3.23 5.89  
 
52 
  
1.84 2.35   
 
53 
  
2.82 3.57 3.64  
 
54 
  
6.23 4.88 3.64  
 
55 
  
8.60 5.66 3.02  
 
56 
  
1.29    
 
57 
  
9.6 11.65 6.33  
 
58 
 
 
1.20    
 
59 
 
 
7.98 2.41 4.18 3.64 
 
60 
  
  2.21 2.15 
 
61 
 
 
0.93 -0.45   
a Data is fold change in E-cadherin restoration above a DMSO control as measured by Western blot for compound 
treatment at 10 µM. (TSA = 3.74). 
b Data is fold change in E-cadherin restoration above a DMSO control as measured by In-Cell Western assay for 
compound treatment at 10 µM. (TSA = 2.37).    
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Table 3. 
 
Compound R WB
a 
SW620 
WBa 
H520 
ICWb 
SW620 
ICWb 
H520 
 
62 
  
3.71 6.40 2.59  
 
63 
  
4.98 7.00 3.37  
 
64 
  
4.66 6.78   
 
65 
  
4.78 3.91 2.36  
 
66 
 
 
1.29    
 
67 
  
2.43 3.73 1.29  
 
68 
  
4.99 5.37 2.26  
 
69 
  
11.99 4.43 3.51  
 
70 
  
13.69 4.64 1.16  
 
71 
  
2.04    
 
72 
  
9.6 8.79 4.36  
 
73 
 
 
8.75 5.43 5.80  
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74 
 
 
1.29     
 
75 
 
 
5.38 5.14 2.80  
 
76 
  
1.84    
 
77 
 
 
2.52 0.64 0.91 1.42 
 
78 
  
  2.24 1.87 
 
79 
 
 
  1.36 -1.95 
 
80 
  
  5.20 5.40 
 
81 
  
  2.35 4.70 
 
82 
  
  2.65 4.24 
 
83 
  
  0.32 1.59 
 
84 
  
  1.66 146 
 
85 
  
  1.23 1.12 
 
86 
  
2.44 6.89   
 
87 
  
1.58 1.04   
 
88 
  
2.32 5.69 2.00  
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89 
  
1.30    
 
90 
  
0.95    
 
91 
  
2.24 2.60   
a Data is fold change in E-cadherin restoration above a DMSO control as measured by Western blot for compound 
treatment at 10 µM. (TSA = 3.74). 
b Data is fold change in E-cadherin restoration above a DMSO control as measured by In-Cell Western assay for 
compound treatment at 10 µM. (TSA = 2.37).    
Table 4. 
 
Compound R WB
a 
SW620 
WBa 
H520 
ICW 
SW620 
ICW 
H520 
 
92 
  
1.08    
 
93 
  
1.10    
 
94 
  
0.87    
 
95 
 
 
1.24    
 
96 
 
 
0.84    
 
97 
  
0.82    
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98 
  
1.37    
 
99 
  
0.80    
 
100 
  
0.83    
 
101 
  
0.82    
 
102 
  
0.96    
 
103 
 
 
1.04    
 
104 
  
2.11 0.89   
 
105 
  
1.38    
a Data is fold change in E-cadherin restoration above a DMSO control as measured by Western blot for compound 
treatment at 10 µM. (TSA = 3.74).  
 
 
   
 161 
Table 5. 
 
Compound R WB
a 
SW620 
WBa 
H520 
ICWb 
SW620 
ICWb 
H520 
 
106 
  
2.10 2.93 1.28  
 
107 
  
2.67 3.65 1.61  
 
108 
 
 
1.39    
 
109 
  
2.78 3.90 2.09  
 
110 
 
 
4.16 4.05 1.73  
 
111 
  
1.72  1.07  
 
112 
  
3.50  1.71  
 
113 
  
1.07    
 
114 
  
1.29  0.87  
 
115 
  
1.27  1.04  
 
116 
  
7.23 8.69 5.68  
 
117 
  
0.96  0.73  
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118 
 
 
1.03    
 
119 
 
 
10.27 2.55 1.48  
 
120 
  
  1.65 1.38 
 
121 
 
 
  1.23 0.21 
 
122 
 
 
6.41 9.91 1.81  
 
123 
  
2.90 3.78   
 
124 
 
 
1.44 1.16 0.95  
 
125 
  
1.67 1.21   
 
126 
  
2.68 7.54   
 
127 
  
  1.19 0.96 
a Data is fold change in E-cadherin restoration above a DMSO control as measured by Western blot for compound 
treatment at 10 µM. (TSA = 3.74). 
b Data is fold change in E-cadherin restoration above a DMSO control as measured by In-Cell Western assay for 
compound treatment at 10 µM. (TSA = 2.37).    
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Table 6. 
 
Compound R WB
a 
SW620 
WBa 
H520 
ICWb 
SW620 
ICWb 
H520 
 
128 
  
1.01  1.23  
 
129 
  
1.00  0.90  
 
130 
  
1.23  1.52  
 
131 
  
1.20  1.13  
 
132 
 
 
1.14  1.01  
 
133 
 
 
1.17    
 
134 
  
0.96  0.96  
 
135 
 
 
0.96  0.95  
 
136 
  
1.06  0.99  
 
137 
  
0.90    
 
138 
  
0.94  1.12  
a Data is fold change in E-cadherin restoration above a DMSO control as measured by Western blot for compound 
treatment at 10 µM. (TSA = 3.74). 
b Data is fold change in E-cadherin restoration above a DMSO control as measured by In-Cell Western assay for 
compound treatment at 10 µM. (TSA = 2.37).  
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Table 7. 
 
Compound R WB
a 
SW620 
WBa 
H520 
ICWb 
SW620 
ICWb 
H520 
 
139 
  
1.94 0.73 1.32  
 
140 
 
 
1.71 1.12 0.94  
 
141 
  
2.09 1.03 1.01  
 
142 
  
2.01 3.61 1.45  
 
143 
 
 
1.17    
 
144 
  
1.97 1.70 1.08  
 
145 
  
1.00  1.28  
 
146 
 
 
1.31  1.50  
 
147 
  
1.07  1.14  
 
148 
  
0.90  0.94  
 
149 
  
1.18    
a Data is fold change in E-cadherin restoration above a DMSO control as measured by Western blot for compound 
treatment at 10 µM. (TSA = 3.74). 
b Data is fold change in E-cadherin restoration above a DMSO control as measured by In-Cell Western assay for 
compound treatment at 10 µM. (TSA = 2.37). 
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Table 8. 
 
Compound R WB
a 
SW620 
WBa 
H520 
ICW 
SW620 
ICW 
H520 
 
150 
  
1.03    
 
151 
  
0.85    
 
152 
  
1.15    
 
153 
 
 
0.83    
 
154 
  
0.78    
 
155 
  
0.97    
 
156 
 
 
0.90    
 
157 
  
0.88    
 
158 
  
0.91    
 
159 
  
0.71    
 
160 
  
8.30 0.95   
a Data is fold change in E-cadherin restoration above a DMSO control as measured by Western blot for compound 
treatment at 10 µM. (TSA = 3.74).  
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Table 9. 
 
Compound R WB
a 
SW620 
WBa 
H520 
ICW 
SW620 
ICW 
H520 
 
161 
  
0.96    
 
162 
  
0.93    
 
163 
 
 
0.83    
 
164 
  
0.64    
 
165 
  
0.74    
 
166 
  
1.22    
 
167 
  
0.87    
 
168 
  
0.74    
 
169 
  
0.63    
 
170 
  
3.53 0.97   
a Data is fold change in E-cadherin restoration above a DMSO control as measured by Western blot for compound 
treatment at 10 µM. (TSA = 3.74).    
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Table 10. 
 
Compound R WB
a 
SW620 
WBa 
H520 
ICW 
SW620 
ICW 
H520 
 
171 
  
1.56    
 
172 
 
 
1.15    
 
173 
  
0.97    
 
174 
  
1.15    
 
175 
  
1.33 1.10   
 
176 
  
1.23    
 
177 
  
1.26 1.47   
 
178 
 
 
1.27    
a Data is fold change in E-cadherin restoration above a DMSO control as measured by Western blot for compound 
treatment at 10 µM. (TSA = 3.74).     
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Table 11. 
 
Compound R WB
a 
SW620 
WBa 
H520 
ICWb 
SW620 
ICWb 
H520 
 
179 
 
 
1.88 2.07 1.08  
 
180 
  
2.92 3.36 2.15  
 
181 
  
3.78 3.26 1.91  
 
182 
  
4.48 3.40 3.78  
 
183 
  
3.54 3.17 3.01  
 
184 
 
 
1.72 1.53 1.43  
 
185 
  
4.20 3.54 1.50  
 
186 
  
2.96 3.48 1.76  
a Data is fold change in E-cadherin restoration above a DMSO control as measured by Western blot for compound 
treatment at 10 µM. (TSA = 3.74). 
b Data is fold change in E-cadherin restoration above a DMSO control as measured by In-Cell Western assay for 
compound treatment at 10 µM. (TSA = 2.37).    
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Table 12. 
 
Compound R WB
a 
SW620 
WBa 
H520 
ICWb 
SW620 
ICWb 
H520 
 
187 
 
 
1.09  1.06  
 
188 
  
1.08  0.94  
 
189 
  
1.17  1.01  
 
190 
  
1.79  1.14  
 
191 
  
1.52  1.34  
 
192 
 
 
1.48  1.19  
 
193 
  
1.50  0.80  
 
194 
  
1.70  0.90  
a Data is fold change in E-cadherin restoration above a DMSO control as measured by Western blot for compound 
treatment at 10 µM. (TSA = 3.74). 
b Data is fold change in E-cadherin restoration above a DMSO control as measured by In-Cell Western assay for 
compound treatment at 10 µM. (TSA = 2.37).   
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Table 13. 
 
Compound R WB
a 
SW620 
WBa 
H520 
ICW 
SW620 
ICW 
H520 
 
195 
 
 
1.08    
 
196 
  
1.08    
 
197 
  
1.15    
 
198 
  
1.01    
 
199 
  
0.88    
 
200 
 
 
1.10    
 
201 
  
0.82    
 
202 
  
1.22    
 
203 
  
1.29    
 
204 
  
1.25    
 
205 
  
1.22    
 
206 
  
1.30    
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207 
 
 
1.10    
a Data is fold change in E-cadherin restoration above a DMSO control as measured by Western blot for compound 
treatment at 10 µM. (TSA = 3.74).    
Table 14. 
 
Compound R WB SW620 
WB 
H520 
ICWa 
SW620 
ICWa 
H520 
 
208 
  
  2.17 1.41 
 
209 
 
 
  2.11 1.26 
 
210 
 
 
  2.47 2.00 
 
211 
 
 
  2.48 1.27 
 
212 
 
 
  2.12 1.30 
 
213 
 
 
  2.63 2.19 
 172 
 
214 
 
 
  1.03 1.09 
 
215 
  
  1.46 1.11 
 
216 
 
 
  1.67 1.28 
a Data is fold change in E-cadherin restoration above a DMSO control as measured by In-Cell Western assay for 
compound treatment at 10 µM. (TSA = 2.37).    
Table 15. 
 
Compound R WB SW620 
WB 
H520 
ICWa 
SW620 
ICWa 
H520 
 
217 
 
 
  2.10 1.55 
 
218 
  
  2.22 1.27 
 
219 
  
  2.35 1.18 
 
220 
  
  2.05 1.40 
 
221 
  
  2.02 1.60 
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222 
 
 
  0.87 1.01 
 
223 
  
  1.63 2.12 
 
224 
  
  1.91 1.82 
 
225 
  
  2.08 1.42 
 
226 
  
  2.36 1.39 
 
227 
  
  1.61 1.18 
 
228 
  
  1.57 1.04 
 
229 
 
 
  1.29 2.02 
a Data is fold change in E-cadherin restoration above a DMSO control as measured by In-Cell Western assay for 
compound treatment at 10 µM. (TSA = 2.37).   
 
 
 
 
 
 
 
 
 174 
Table 16. 
 
Compound R WB SW620 
WB 
H520 
ICWa 
SW620 
ICWa 
H520 
 
230 
 
 
  1.50 1.19 
 
231 
  
  0.65 1.44 
 
232 
  
  1.44 1.51 
 
233 
  
  1.06 1.26 
 
234 
  
  1.12 1.22 
 
235 
  
  0.88 1.06 
 
236 
  
  1.24 1.08 
 
237 
  
  1.38 1.16 
 
238 
  
  1.27 1.42 
 
239 
 
 
  0.96 1.12 
 
240 
  
  1.08 1.28 
a Data is fold change in E-cadherin restoration above a DMSO control as measured by In-Cell Western assay for 
compound treatment at 10 µM. (TSA = 2.37).   
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Table 17.  
 
Compound R WB SW620 
WB 
H520 
ICWa 
SW620 
ICWa 
H520 
 
241 
 
 
  1.38 1.34 
 
242 
  
  1.41 1.05 
 
243 
  
  0.86 0.61 
 
244 
  
  0.79 0.41 
 
245 
 
 
  1.23 1.36 
 
246 
  
  1.37 1.24 
 
247 
  
  0.75 0.21 
 
248 
  
  0.89 2.32 
 
249 
  
  1.20 1.12 
 
250 
  
  1.15 0.97 
 
251 
 
 
  0.91 0.07 
 176 
 
252 
  
  0.64 -0.38 
 
253 
 
  1.08 0.61 
 
254 
 
 
  1.04 0.27 
a Data is fold change in E-cadherin restoration above a DMSO control as measured by In-Cell Western assay for 
compound treatment at 10 µM. (TSA = 2.37). 
  
 
Table 18. 
 
Compound R WB SW620 
WB 
H520 
ICWa 
SW620 
ICWa 
H520 
 
255 
 
 
  1.02 2.47 
 
256 
 
 
  1.27 0.92 
 
257 
  
  1.26 1.18 
 
258 
  
  1.03 1.07 
 
259 
  
  1.21 1.29 
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260 
 
 
  1.00 1.11 
 
261 
  
  1.35 1.07 
 
262 
  
  0.96 1.00 
 
263 
  
  1.42 1.23 
 
264 
  
  1.04 1.25 
 
265 
  
  1.02 1.29 
 
266 
 
 
  0.68 0.91 
 
267 
  
  1.13 1.35 
 
268 
  
  0.83 1.37 
a Data is fold change in E-cadherin restoration above a DMSO control as measured by In-Cell Western assay for 
compound treatment at 10 µM. (TSA = 2.37).   
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Table 19.  
Compound Compound 
 
 
 
269 
ICWa SW620: 0.86 
 
 
 
270 
ICW SW620: 0.91 
 
 
 
271 
ICW SW620: 1.97 
ICW H520: 4.07 
 
 
 
 
272 
ICW SW620: 0.95 
ICW H520: 2.30 
 
 
 
 
273 
ICW SW620: 0.87 
ICW H520: 0.86 
 
 
 
274 
ICW SW620: 1.03 
ICW H520: 1.06 
 
 179 
 
 
275 
ICW SW620: 0.93 
ICW H520: 1.13 
 
 
276 
ICW SW620: 0.90 
ICW H520: 1.38 
 
 
 
 
277 
ICW SW620: 1.07 
ICW H520: 1.41 
 
 
 
 
 
 
278 
ICW SW620: 0.75 
ICW H520: 1.05 
 
 
 
279 
ICW SW620: 1.38 
ICW H520: 0.67 
 
 
280 
ICW SW620: 0.75 
ICW H520: 1.65 
 
 
281 
ICW SW620: 1.15 
ICW H520: 2.04 
 
 
 
 
 
282 
ICW SW620: 0.87 
ICW H520: 1.31 
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283 
ICW SW620: 1.55 
ICW H520: 2.82 
 
 
284 
ICW SW620: 1.11 
ICW H520: 2.21 
 
 
285 
ICW SW620: 0.89 
ICW H520: 0.98 
 
 
a Data is fold change in E-cadherin restoration above a DMSO control as measured by In-Cell Western assay for 
compound treatment at 10 µM. (TSA = 2.37).         
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Table 20. 
 
Compound X n R ICW
a 
SW620 
EC50 
(μM) 
ICWa 
H520 
EC50 
(μM) 
 
286 
 
NH 1 
 
1.37  1.24  
 
287 
 
NH 1 
 
1.45  1.04  
 
288 
 
NH 1 
 
1.77  1.10  
 
289 
 
O 2 
 
5.23 5.0 5.54 1.0 
 
290 
 
NH 1 
 
1.29  1.22  
 
291 
 
O 2 
 
4.92 4.97 5.92 1.5 
 
292 
 
O 2 
 
2.92 5.0 5.27 1.4 
 
293 
 
O 2 
 
1.62  1.88  
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294 
 
O 1 
 
3.40 3.7 3.51 5.6 
 
295 
 
O 1 
 
2.79 8.8 2.87 5.1 
 
296 
 
O 1 
 
 
 
1.18  1.14  
 
297 
 
O 1 
 
8.98 4.8 4.22  
 
298 
 
O 1 
 
3.05 7.1   
a Data is fold change in E-cadherin restoration above a DMSO control as measured by In-Cell Western assay for 
compound treatment at 10 µM. (TSA = 2.37).             
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Table 21. Displays the EC50 values calculated for selected analogs.  Concentration response 
curves were developed from seven treatment concentrations from 30 to 0.1 μM using the In-Cell 
Western assay. 
Compound SW620 EC50  (μM) 
H520 EC50  
(μM) 
 
1 10.6 5.4 
 
39 5.6  
 
40 1.8  
 
41 5.8  
 
54 6.0 2.5 
 
57 2.13 1.25 
 
73 1.5 2.0 
 
80 7.0  
 
81 1.5  
 
82 5.0  
 
116 4.5 1.6 
 
289 5.0 1.0 
 
291 4.97 1.5 
 
292 5.0 1.4 
 
294 3.7 5.6 
 
295 8.8 5.1 
 
297 4.8  
 
298 
 
7.1       
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Table 1. Displays the various numbering schemed that have been used throughout the project, 
so that compounds can be easily identified in lab notebooks (Y/R code) and/or requested for 
further use if necessary (VU#). 
Thesis # VU ID Lab Code 
 
1 VU0075630 R21 
5 VU0364639-1 1J 
6 VU0364640-1 2J 
7 VU0364641-1 3J 
8 VU0364441-1 12Y 
9 VU0152198-4 13Y 
10 VU0364442-1 14Y 
11 VU0364443-1 15Y 
12 VU0364444-1 16Y 
13 VU0364445-1 17Y 
14 VU0364446-1 18Y 
15 VU0364447-1 19Y 
16 VU0364448-1 20Y 
17 VU0364449-1 21Y 
18 VU0364450-1 22Y 
19 VU0364451-1 23Y 
20 VU0364452-1 24Y 
21 VU0075620-6 25Y 
22 VU0364453-1 26Y 
23 VU0364454-1 27Y 
24 VU0233088-5 28Y 
25 VU0364455-1 29Y 
26 VU0364456-1 30Y 
27 VU0364457-1 31Y 
28 VU0364458-1 32Y 
29 VU0365319-2 46Y 
30 VU0210058-4 47Y 
31 VU0405342-1 94Y 
32 VU0405346-1 98Y 
33 VU0229479-3 102Y 
34 VU0409653-1 134Y 
35 VU0409657-1 138Y 
 186 
36 VU0413357-1 181Y 
37 VU0413361-1 185Y 
38  213Y 
39 VU0449695-1 248Y 
40 VU0449697-1 250Y 
41 VU0449699-1 252Y 
42 VU0449701-1 254Y 
43 VU0142371-2 33Y 
44 VU0365822-1 34Y 
45 VU0365823-1 35Y 
46 VU0109076-2 36Y 
47 VU0285856-3 48Y 
48 VU0403135-1 49Y 
49 VU0403136-1 50Y 
50 VU0403137-1 51Y 
51 VU0403138-1 52Y 
52 VU0403139-1 53Y 
53 VU0326279-2 54Y 
54 VU0405343-1 95Y 
55 VU0405347-1 99Y 
56 VU0228184-4 103Y 
57 VU0409654-1 135Y 
58 VU0409658-1 139Y 
59 VU0413358-1 182Y 
60 VU0413362-1 186Y 
61  214Y 
62 VU0365824-1 37Y 
63 VU0365825-1 38Y 
64 VU0329150-3 39Y 
65 VU0403140-1 55Y 
66 VU0403141-1 56Y 
67 VU0180426-4 57Y 
68 VU0403142-1 58Y 
69 VU0405344-1 96Y 
70 VU0405348-1 100Y 
71 VU0180488-5 104Y 
72 VU0409655-1 136Y 
 187 
73 VU0409675-1 156Y 
74 VU0409659-1 140Y 
75 VU0180398-4 157Y 
76 VU0409676-1 158Y 
77 VU0413359-1 183Y 
78 VU0413363-1 187Y 
79  215Y 
80 VU0449694-1 247Y 
81 VU0449696-1 249Y 
82 VU0449698-1 251Y 
83 VU0449700-1 253Y 
84 VU0451771-1 256Y 
85 VU0451842-1 257Y 
86 VU0180016-5 1Y 
87 VU0180488-4 4Y 
88 VU0181409-5 6Y 
89 VU0362438-1 7Y 
90 VU0362440-1 9Y 
91 VU0362436-1 3Y 
92 VU0362439-1 8Y 
93 VU0293163-2 10Y 
94 VU0404056-1 74Y 
95 VU0404057-1 75Y 
96 VU0365333-2 76Y 
97 VU0364642-2 77Y 
98 VU0404058-1 78Y 
99 VU0405557-1 106Y 
100 VU0405558-1 107Y 
101 VU0365337-2 108Y 
102 VU0405559-1 109Y 
103 VU0365334-1 30J 
104 VU0365335-1 31J 
105 VU0365336-1 32J 
106 VU0404063-1 88Y 
107 VU0404064-1 89Y 
108 VU0404065-1 90Y 
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109 VU0404066-1 91Y 
110 VU0404067-1 92Y 
111 VU0405345-1 97Y 
112 VU0405349-1 101Y 
113 VU0405350-1 105Y 
114 VU0405560-1 110Y 
115 VU0405561-1 111Y 
116 VU0409656-1 137Y 
117 VU0405562-1 112Y 
118 VU0409660-1 141Y 
119 VU0413360-1 184Y 
120 VU0413364-1 188Y 
121  216Y 
122 VU0365327-1 23J 
123 VU0365328-1 24J 
124 VU0365329-1 25J 
125 VU0365330-1 26J 
126 VU0365332-1 28J 
127 VU0451770-1 255Y 
128 VU0365826-1 40Y 
129 VU0365827-1 41Y 
130 VU0365828-1 42Y 
131 VU0365829-1 43Y 
132 VU0403143-1 59Y 
133 VU0403144-1 60Y 
134 VU0403145-1 61Y 
135 VU0403146-1 62Y 
136 VU0403147-1 63Y 
137 VU0403148-1 64Y 
138 VU0403149-1 65Y 
139 VU0365830-1 44Y 
140 VU0365831-1 66Y 
141 VU0075446-6 45Y 
142 VU0404051-1 67Y 
143 VU0404052-1 68Y 
144 VU0404053-1 69Y 
145 VU0186810-5 70Y 
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146 VU0404054-1 71Y 
147 VU0404055-1 72Y 
148 VU0075466-2 73Y 
149 VU0409674-1 155Y 
150 VU0404059-1 79Y 
151 VU0404060-1 80Y 
152 VU0365340-2 81Y 
153 VU0404061-1 82Y 
154 VU0245555-5 83Y 
155 VU0404062-1 84Y 
156 VU0365338-2 85Y 
157 VU0365339-2 85Y 
158 VU0347121-2 87Y 
159 VU0364644-1 8J 
160 VU0365341-1 37J 
161 VU0405563-1 113Y 
162 VU0405564-1 114Y 
163 VU0405565-1 115Y 
164 VU0364645-2 116Y 
165 VU0187080-4 117Y 
166 VU0240112-5 93Y 
167 VU0364646-1 10J 
168 VU0042509-5 11J 
169 VU0364647-1 12J 
170 VU0365342-1 39J 
171 VU0365321-1 16J 
172 VU0032890-5 17J 
173 VU0365322-1 18J 
174 VU0365323-1 19J 
175 VU0365324-1 20J 
176 VU0365325-1 21J 
177 VU0365326-1 22J 
178 VU0365320-1 15J 
179 VU0405566-1 118Y 
180 VU0405567-1 119Y 
181 VU0405568-1 120Y 
182 VU0405569-1 121Y 
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183 VU0405570-1 122Y 
184 VU0405571-1 123Y 
185 VU0405572-1 124Y 
186 VU0405573-1 125Y 
187 VU0405574-1 126Y 
188 VU0405575-1 127Y 
189 VU0405576-1 128Y 
190 VU0405577-1 129Y 
191 VU0405578-1 130Y 
192 VU0405579-1 131Y 
193 VU0405580-1 132Y 
194 VU0405581-1 133Y 
195 VU0409661-1 142Y 
196 VU0409662-1 143Y 
197 VU0409663-1 144Y 
198 VU0409664-1 145Y 
199 VU0409665-1 146Y 
200 VU0409666-1 147Y 
201 VU0409667-1 148Y 
202 VU0409668-1 149Y 
203 VU0409669-1 150Y 
204 VU0409670-1 151Y 
205 VU0409671-1 152Y 
206 VU0409672-1 153Y 
207 VU0409673-1 154Y 
208 VU0413335-1 159Y 
209 VU0413336-1 160Y 
210 VU0413337-1 161Y 
211 VU0413338-1 162Y 
212 VU0413339-1 163Y 
213 VU0413340-1 164Y 
214 VU0413341-1 165Y 
215 VU0413342-1 166Y 
216 VU0413343-1 167Y 
217 VU0413344-1 168Y 
218 VU0413345-1 169Y 
219 VU0413346-1 170Y 
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220 VU0413347-1 171Y 
221 VU0413348-1 172Y 
222 VU0413349-1 173Y 
223 VU0413350-1 174Y 
224 VU0413351-1 175Y 
225 VU0413352-1 176Y 
226 VU0413353-1 177Y 
227 VU0413354-1 178Y 
228 VU0413355-1 179Y 
229 VU0413356-1 180Y 
230  189Y 
231  190Y 
232  191Y 
233  192Y 
234  193Y 
235  194Y 
236  195Y 
237  196Y 
238  197Y 
239  198Y 
240  199Y 
241  200Y 
242  201Y 
243  202Y 
244  203Y 
245  204Y 
246  205Y 
247  206Y 
248  207Y 
249  208Y 
250  209Y 
251  210Y 
252  211Y 
253  212Y 
254  217Y 
255  218Y 
256  219Y 
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257  220Y 
258  221Y 
259  222Y 
260  223Y 
261  224Y 
262  225Y 
263  226Y 
264  227Y 
265  228Y 
266  229Y 
267  230Y 
268  231Y 
269 VU0362435-1 2Y 
270 VU0362437-1 5Y 
271 VU0449020-1 232Y 
272 VU0449019-1 233Y 
273 VU0449018-1 234Y 
274 VU0449017-1 235Y 
275 VU0449016-1 236Y 
276 VU0449015-1 237Y 
277 VU0449014-1 238Y 
278 VU0449013-1 239Y 
279 VU0449012-1 240Y 
280 VU0449008-1 241Y 
281 VU0449009-1 242Y 
282 VU0449021-1 243Y 
283 VU0449022-1 244Y 
284 VU0449010-1 245Y 
285 VU0449011-1 246Y 
286 VU0452047-1 258Y 
287 VU0452036-1 264Y 
288 VU0452982-1 269Y 
289 VU0452046-1 259Y 
290 VU0452952-1 266Y 
291 VU0452045-1 260Y 
292 VU0452033-1 261Y 
293 VU0452035-1 263Y 
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294 VU0452034-1 262Y 
295 VU0452953-1 267Y 
296 VU0452951-1 265Y 
297 VU0452954-1 268Y 
298 VU0452983-1 270Y 
* Some compounds do not have VU# as they were not registered through the system at Vanderbilt University.  These 
compounds can be found in a freezer in the lab or easily synthesized using the protocol provided in Chapter 2 and/or 
Appendix Table for which they are located.    
